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Abstract
MATTHEW GUSTAV SOLOMON. Role of BDNF in the Ability of Exercise to
Attenuate Dependence-Related Escalated Alcohol Drinking in C57BL/6J Mice.
(Under the direction of HOWARD BECKER)

Alcohol use disorder (AUD) continues to be a burden to society. Currently,
few efficacious treatments exist. In addition to behavioral therapy and support
groups (e.g. Alcoholics Anonymous), there are only three FDA approved
pharmacotherapies. The lack of treatment options for alcohol addiction denotes
the need to discover and develop new strategies and pharmacological targets to
improve abstinence, prevent relapse, and inhibit the development of alcohol
addiction. Chronic alcohol exposure reduces brain-derived neurotrophic factor
(BDNF) in the medial prefrontal cortex (mPFC). Reductions of BDNF in the mPFC
drive alcohol-dependent drinking in mice and conversely, elevating BDNF in this
region blocks alcohol dependence-related drinking. Therefore, enhancing TrkB
(BDNF primary receptor) activity in the mPFC, by pharmacological activation or
increased expression of BDNF via exercise, may provide a new treatment strategy
for AUD. To engender alcohol dependence mice are exposed to repeated cycles
of chronic intermittent ethanol (CIE) vapor, producing escalated alcohol drinking
compared to Baseline and control (Air) mice. Additionally, deficits in Bdnf mRNA
and protein are seen in the mPFC after CIE exposure. Exercise (wheel running)
noninvasively induces BDNF expression in the dentate gyrus (DG) of rodents and
vii

in the blood of humans. This information led to the question of whether exercise
could increase BDNF in the mPFC, reduce alcohol dependence-related drinking,
and if this effect would occur through a BDNF-TrkB mediated mechanism. Studies
tested the hypothesis that: Daily, limited (2-hr) voluntary wheel running would
increase BDNF expression in the brain and through BDNF-TrkB signaling,
attenuate CIE-induced escalated alcohol drinking. Following the Introduction,
Chapter 2 demonstrates mice given limited access to a running wheel every day
for several weeks, show increased Bdnf mRNA (qRT-PCR) and BDNF protein
(ELISA) expression in the mPFC and DG. Building on these findings, Chapter 3
shows exercise attenuates CIE induced escalated alcohol drinking and mitigates
reductions of BDNF mRNA in the mPFC caused by chronic alcohol exposure.
Finally, in Chapter 4, using pharmacological inhibition of TrkB receptors, the ability
of exercise to attenuate escalated alcohol intake is prevented. Taken together this
study demonstrates exercise attenuates escalated alcohol intake in a model of
dependence via BDNF-TrkB mediated signaling.
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Chapter 1 - Introduction
Alcohol Use Disorder (AUD)
Background
Alcohol is the most commonly used drug in America, with close to half the world’s
population consuming alcohol (1) . Excessive alcohol use can lead to the development of
alcohol use disorder (AUD), a chronic, relapsing brain disordered afflicting 16 million
Americans (2). The occurrence of AUD in a year is approximately 14% of the population,
with 20% of people meeting the clinical diagnostics in their lifetime for AUD (3, 4). To be
diagnosed with AUD the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
requires at least 2 out of the 11 criteria to be met within a 12-month period. Alcohol abuse
can lead to alcohol dependence (5). Dependence is characterized by compulsive alcohol
intake, loss of control of drinking, preoccupation with alcohol, increased tolerance leading
to the need for more alcohol to have the same effect, negative affective states during
withdrawal, and continued used despite negative physical and social consequence (6).
Worldwide 3.3 million deaths are attributed to alcohol use, making AUD a leading
cause of preventable death (7, 8). Alcohol use disorder places a large financial burden on
the US economy through direct and indirect healthcare costs, crime, and loss of work
productivity costing $249 billion in 2010 (9, 10). Social and physical health issues
commonly co-occur with AUD, with psychiatric disorders such as anxiety and depression
increasing with heavy alcohol use (11, 12). Alcohol use problems are common in patients
with mental health disorders (13), where alcohol is commonly used to self-medicate in
order to treat mental health disorders that often exist prior to the development of AUD (14,
15).
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The risk for alcohol abuse and developing dependence is increased when drinking
begins as an adolescence (16). Dangerous drinking behaviors are commonly associated
with other risky behaviors including unprotected sex, driving under the influence, drug use,
injuries, and criminal activity (17, 18), contributing to the adverse health and social
consequences linked to AUD. Alcohol intoxication is commonly associated with domestic
violence, deaths from homicide and suicide, child abuse, driving related injuries and death
(19).
Binge drinking is a common, hazardous form of drinking, where greater than 4 drinks
in females or 5 in males are consumed in a 2-hour period, resulting in blood ethanol
concentration (BEC) levels of greater than 80 mg/dl (20, 21). Repeated cycles of heavy
alcohol use or binge drinking followed by periods of abstinence can alter brain circuitry
related to reward, motivation, and inhibitory control leading to the development of alcohol
dependence, with alcohol use continuing despite negative physical and social
consequences (2). This cycle leads to morphological, structural, and molecular changes
in the brain (22, 23).
Despite the large number of people affected by, and the dangers associated with
AUD only 8.3% of users seek and receive treatment (4). Treatments include behavioral
therapy, group support (e.g. Alcoholics Anonymous), and pharmacological treatment ((2428)). Current FDA approved pharmacotherapies are not adequately effective at the
population level (29-31). Of those that do receive treatment, it often occurs years after the
onset of the disorder (32, 33). Accessibility to treatment, due to cost or lack of health
insurance coverage, is one limitation faced by those afflicted. Relapse occurs in up to 60%
of treatment seekers mediated by interaction of multiple social, physiological, and
psychological interactions (34-37). With the prevalence and magnitude of the AUD
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problem, the high rate of relapse, and the dearth of treatment options available, it is critical
that new targets and therapies are elucidated and developed to prevent the development
of alcohol dependence and to improve treatment outcomes.

Stages of Alcohol Addiction
Alcohol addiction is a chronic, relapse brain disorder, comprised of multiple
psychological and neurobiological factors. Multiple theories of addiction have been
proposed, each addressing different aspects of the behavior, thoughts, and feelings that
occurring at different stages throughout the cycle of addiction (for review see 38). While
many of these theories address certain specific behaviors, the addiction cycle is more
commonly viewed as being comprised of three stages, where within these stages more
specific theories are found.
In the generally accepted 3-stage cycle of alcohol addiction the first stage involves
alcohol binging and intoxication, which is followed by the second stage where an individual
suffers negative affect caused by alcohol withdrawal. Finally, in the third stage craving,
preoccupation, and anticipation for alcohol occurs, initially for the rewarding effects but
transitioning to a need for alcohol to reduce the negative affect associated with withdrawal
(2, 6). This cyclical pattern leads to dysfunction in the pathways controlling reward,
compulsive-habit, and inhibitory control driving excess alcohol drinking (38, 39).

Binge/Intoxication
The first stage in the development of alcohol addiction involves binge drinking and
intoxication. Binge drinking is defined as a pattern of dangerous, excessive drinking
leading to BECs (40) of 80mg% or greater, resulting in intoxication (20, 41). In men this is
commonly ≥5 drinks and in women ≥4 drinks in a 2-hr period (42). Repeated bouts of
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binge drinking lead to a greater risk of alcohol dependence and neurodegeneration (43,
44). Neuronal degeneration can exacerbate alcohol dependence related symptoms, as
degeneration in the circuitry connecting the amygdala and frontal cortex is associated with
increased alcohol consumption and reduced behavioral control (45-47).
Changes in neurochemical release and signaling occur throughout the addiction
process. In the early stages of drug and alcohol use the mesocorticostriatal dopamine
system plays a key role in the rewarding effects and reinforcing properties of drugs (48).
For example, alcohol use increases midbrain dopaminergic activity in humans and rats,
mediating the positive-reinforcing properties of alcohol (2, 49, 50). Additionally, glutamate
signaling is initially reduced by acute alcohol use and then transitions into enhanced
signaling after chronic alcohol exposure (51). Furthermore, low doses of alcohol can
reduce the release of excitatory neurotransmitters e.g. dopamine, through inhibiting the
function of glutamate receptors (NMDA and mGluR5) (52-54).
Although glutamatergic signaling is decreased during acute intoxication, presynaptic
release of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) (55) is
enhanced, increasing postsynaptic GABA receptor activity (56). The duration of alcohol
exposure differentially affects GABA receptor function. Exposure to alcohol at acute and
sub-chronic levels results in increased GABA receptor functioning, with chronic exposure
down-regulating GABAergic signaling (57-59). The role of GABA receptors in intoxication
are further demonstrated by administration of the GABA receptor agonist baclofen, which
reduces relapse in humans and decreases alcohol intake in rats (60, 61).
Not only is excitatory and inhibitory neurotransmitter signaling affected by alcohol
use, but alcohol can dysregulate glucocorticoid signaling, affecting the motivational
aspects of alcohol use (62). During intoxication the stress hormone corticosterone is
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significantly elevated before displaying a reduction in expression where levels can remain
depressed for several weeks after chronic alcohol exposure (63, 64).
During the binge and intoxication phase of the addiction cycle when alcohol is
acutely administered, the reward threshold is reduced. As an individual transitions into
dependence and chronically uses alcohol deficits in striatal dopamine (DA) emerge,
disrupting normal reward processing and increasing the reward threshold, requiring higher
levels of alcohol intake to produce the same effect (65).

Withdrawal/Negative Affect
When heavy drinking and intoxication is ceased, alcohol withdrawal syndrome
occurs over the following hours to days. Withdrawal is a negative affective state consisting
of stress, increased anxiety, CNS hyperexcitability, autonomic nervous system activation,
and in severe cases delirium tremens (66, 67). Symptoms of alcohol withdrawal syndrome
include anxiety, depressed mood, sleep disturbance, and anhedonia (68). Physical
withdrawal symptoms usually subside within several days, but other symptoms can persist
for weeks to months. (68). Physical symptoms mark acute withdrawal, while in prolonged
abstinence a shift toward negative affect drives craving and relapse (69).
Multiple neuromolecular signaling pathways are involved in the negative affect of
withdrawal. For example, alcohol withdrawal produces reductions in DA and serotonin (5HT) activity in the nucleus accumbens (NAc) of rats (70, 71). These molecules are involved
in behaviors such as irritability, aggression, and attention, commonly associated with
negative symptoms of withdrawal (72, 73). Additionally, during withdrawal there is
increased glutamatergic and reduced GABA signaling, which produces anxiety and
dysphoria (57). Glucocorticoid signaling is increased in the mPFC during abstinence and
is associated with depression, drug withdrawal and craving (74, 75). Glucocorticoid
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receptor antagonism during abstinence decreases alcohol intake, with direct antagonism
in the mPFC attenuating memory deficits seen during alcohol withdrawal (62, 76).
The opioid system has emerged as an important player in alcohol withdrawal.
Chronic alcohol dysregulates the opioid system, altering affective states, leading to
relapse. Treatment with the µ-opioid receptor antagonist naltrexone during withdrawal has
been shown to decrease the urge to drink and when drinking did occur it reduced the
number of drinks consumed (77, 78). Dynorphin (DYN) is an endogenous opioid that binds
to the k-opioid receptor (KOR), a G-protein coupled receptor. Expression of DYN and KOR
is throughout the reward and stress circuitry playing a role in affective states during
withdrawal and alcohol upregulates DYN and KORs (79, 80). Withdrawal increases
DYN/KOR signaling and activation of KOR producing dysphoria and reducing dopamine
in the striatum (81, 82). In addition, antagonism of KOR increases DA release and reduces
alcohol intake (83, 84). Demonstrating the role of the DYN/KOR system in negative affect
of withdrawal, leading to relapse of alcohol drinking.

Preoccupation/Anticipation (aka craving)
The final stage in the cycle of addiction, which is enhanced by withdrawal symptoms,
is craving for alcohol. Craving is the preoccupation and anticipation with obtaining drugs
or alcohol, commonly described as a shift from goal-directed to compulsive “habit”
behavior and the inability to control the desire and impulse to drink (85). Heavy alcohol
use enhances sensitivity to cues and stress that can trigger craving and relapse,
perpetuating alcoholism. Stress activates the HPA axis, releasing glucocorticoids that in
turn modulate DA release in the striatum driving alcohol craving (86-88). Alcoholassociated cues, such as context or smell, or alcohol itself, are major risk factors that
trigger alcohol craving and relapse (89, 90).
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Withdrawal symptoms that can lead to relapse are a physical expression of CNS
dysfunction. Chronic alcohol use results in neuroadaptations which affect reward,
emotional response, and the regulation of alcohol intake. These adaptations can increase
an individual’s susceptibility to stress and alcohol-related cues, exacerbating the risk of
relapse in abstinent alcoholics (85, 91). Even after withdrawal symptoms have subsided,
abstinent alcoholics are more susceptible to stress and cues leading to relapse (92, 93).
In humans, hyperactivity in the vmPFC/ACC and ventral striatum predict alcohol
craving and relapse in abstinent alcoholics (94). The vmPFC/ACC regulate emotional
reward and decision making (95, 96) and the ventral striatum (97) is involved in reward
and craving (2). These regions are connected through glutamatergic projections
emanating from the PFC, controlling dopamine release (2, 98). Deficits in dopaminergic
activity, as a result of chronic alcohol abuse contribute to the craving for alcohol leading
to alcohol-seeking behaviors and relapse (99).
Relapsing alcoholics have been shown to have decreased volume in the amygdala
and atrophy of the frontal cortex compared to healthy controls and nonrelapsing alcoholics
(100, 101). Long-term alcohol abuse leads to reductions in cognitive control of the
prefrontal cortical control over striatum (compulsive behavior and reinforcement) and
amygdala (emotions), weakening the ability to resist craving and relapse to alcohol
seeking and use (102).

The Prefrontal Cortex in Addiction
During the cycle of addiction, the transition from casual alcohol use to abuse and
dependence involves changes in brain circuitry controlling behavior associated with
reward and motivation (103). Not only is AUD a disorder affecting reward seeking and
motivation, but deficits in inhibitory control circuitry are integral in the behavior.
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The prefrontal cortex (PFC) is a key brain region in addiction (104). It controls
executive function, working memory, top-down inhibitory control and behavioral flexibility,
and plays a role in controlling motivational processes of the striatum (105-107). The PFC
is comprised of three sub-regions including the medial prefrontal cortex (mPFC), the
anterior cingulate cortex (ACC), and orbital frontal cortex (OFC). The mPFC can be further
divided into the prelimbic and infralimbic regions (108), which have distinct roles in fear
extinction and expression, inhibitory behavior, and drug-seeking (109, 110). Both the
prelimbic and infralimbic regions of the mPFC control drug responses (111), responding
in a go, no-go manner initiating and inhibiting drug related behaviors (112).
Multiple brain regions in addition to the PFC have been implicated in different
aspects of alcohol use and dependence. Two subcortical regions involved are the striatum
(alcohol reward and reinforcement, and

compulsive alcohol use) (98, 113) and the

amygdala (negative reinforcement, stress, and emotional response) (114). The PFC
sends and receives projections to the amygdala and striatum creating circuits controlling
executive function, negative emotional states, and motivated behavior respectively, which
drive behaviors leading to alcohol use and dependence (115, 116). Heavy alcohol use
and addiction decreases functional connectivity between frontal cortical and these
subcortical regions (37). Glutamatergic afferent from the PFC to the ventral striatum
(nucleus accumbens) regulate DA release (98). Exposure to alcohol causes changes in
this pathway, which underlie the loss of control in addiction. In alcohol dependent rats,
acute abstinence produces a functional disconnection between the PFC and central
amygdala (CeA), through the recruitment of inhibitory neurons from the mPFC, causing
working memory deficits (117). Neuroimaging studies have revealed activation of the PFC
and corticolimbic circuitry in alcoholics responding to alcohol related cues (118, 119).
Enhanced activation of the PFC and striatum to alcohol cues in abstinent alcoholics is a
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predictor of relapse (120). Inactivation of afferents from PFC to NAc attenuate drug
seeking, while inhibiting afferents to the amygdala blocks cue-induced reinstatement
(121).
Prolonged alcohol abuse decreases brain volume, particularly in the frontal cortex
and white matter regions of brain reward systems (122). Cortical thickness is positively
associated with cognitive function and in alcoholics it is shown to be reduced in areas
controlling reward (123). Postmortem and MRI studies with alcoholics show reductions in
neuronal gray and white matter volume, in both males and females, particularly affecting
the frontal lobe (124, 125). It has been observed, people with AUD have deficits in glucose
metabolism leading to cortical atrophy and reductions in cognitive functioning (126). Loss
of function in the PFC can affect control over emotions and behavior leading to craving
and relapse. Relapsing alcoholics displayed greater atrophy in the PFC (OFC, ACC, and
mPFC) relative to control subjects and alcoholics that remained abstinent (101).
Reductions in the volume of mPFC (97) and in the amygdala (100) predicted quicker
relapse in abstinent alcoholics. The structural alterations of the PFC caused by heavy
alcohol use persist even during abstinence, affecting cognitive and inhibitory control over
drug seeking behaviors (127).
Set-shifting and reversal learning are behavioral tasks that involve the PFC. When
the mPFC and OFC are lesioned in rodents and humans impairments in these behaviors
are detected (128, 129). Additionally, human alcoholics and mice exposed to chronic
intermittent alcohol exposure demonstrate deficits in set-shifting and reversal learning,
(130, 131). Indicating that chronic alcohol exposure causes dysfunction in the PFC leading
to impaired decision making demonstrated by alcoholics.
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Stress is a well-known trigger for alcohol use and relapse. Overlap between stress
and reward behavior circuitry are thought to underlie how stress increases alcohol use
and drives relapse (87, 91, 93). In response to stress, adrenocorticotropic hormone
(ACTH) is released from the anterior pituitary and results in the secretion of glucocorticoids
(GCs) from the anterior pituitary. Glucocorticoid receptors (GR) and mineralocorticoid
receptors (MR) and activated by binding of GCs (132) inducing signaling that leads to
changes in genetic and epigenetic regulation, contributing to neurodegeneration and
associated behaviors (132). Antagonism of GRs in the mPFC reduced memory deficits
seen during alcohol withdrawal (76). Chronic alcohol exposure increases GC signaling in
the mPFC in abstinence (74) and antagonism of the GR decreases alcohol intake during
abstinence (62).
This information demonstrates the important role the PFC plays in addiction related
behaviors. Thus, studying the effects of alcohol on the PFC can help elucidate the
mechanisms that regulate addiction behavior to discover possible targets and treatment
strategies for AUD.

Hippocampus
Studies have explored the impact of alcohol use and dependence on hippocampal
structure and function evidencing reductions in hippocampal volume and deficits in
memory and decision making (133-135). However, we are unaware of studies specifically
addressing the role of the hippocampus in alcohol-dependent related drinking. The
hippocampus is well established as a region which is sensitive to the effects of exercise,
producing increases in BDNF expression (mRNA and protein) (136-139). In Chapter 2 the
dentate gyrus subregion of the hippocampus was analyzed to serve as a control region to
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determine if our model of daily, limited (2-hr/day) wheel running would be sufficient to
induce elevated BDNF.

Modeling Alcohol Use and Addiction in Animals
Studying alcohol use and addiction in animal models has been critical to
understanding the neurobiology and mechanisms which drive alcohol-seeking and
drinking behavior. Animal models allow for the controlled testing of pharmacological
agents to determine their efficacy in the treatment of excessive drinking. Several animal
models have been developed to explore the biological and behavioral effects of alcohol
use and exposure. These animal models include invertebrates such as Drosophila
melanogaster (fruit flies), Caenorhabditis elegans (nematode), Danio rerio (zebrafish)
which possess smaller and more simple nervous systems making them excellent tools for
investigating the molecular and cellular basis for addiction (140, 141). Additionally,
nonhuman primate models of substance abuse have been employed for decades (142).
Similarities between the organization of the primate and human brain provide a model that
can elucidate the effect of alcohol on brain structure and function. Furthermore, nonhuman
primates grant researchers with an animal model that allows for the investigation of more
complex behaviors. Finally, rodents including mice, rats, and prairie voles are used to
examine molecular mechanism, neurocircuitry, and behavioral effects of alcohol use and
addiction (143-147). In the following sections we briefly explore rodent models of alcohol
use and dependence that are used in the experiments conducted in subsequent chapters.

Rodents
In the laboratory setting some strains of rodents (eg. C57BL/6J) will voluntarily
consume alcohol (148), providing a useful model for examining alcohol-related behavior.
Alcohol consumption is not limited to the laboratory setting as animals in the wild have
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been found to eat fermented fruits, with some species have been found to eat to the point
of being intoxicated (149).
Not all inbred strains of rodents consume the same level of alcohol. For example,
DBA/2J mice consume significantly less alcohol than C57BL/6J mice, which are known to
have a high preference for alcohol and are commonly used in alcohol related studies (67,
150). Utilizing these different strains of mice can help elucidate genetic and molecular
components that influence alcohol intake. The BXD recombinant mouse line generated by
cross breeding C57BL/6J and DBA/2J produced mice that consumed a range of alcohol
at baseline and after alcohol dependence (151). Genome analysis of a BXD panel
provides information about genes that correlate with drinking related behaviors and
possible pharmacological targets (152, 153). Additionally, selective breeding of high and
low drinking mice and rats from within a given line, such as the generation of HDID mice,
HAD/LAD rats, or P- and NP-rats allow for exploration of genetic, molecular difference
which lead to alcohol related behaviors.

Alcohol Drinking and Dependence Models
Multiple experimental procedures exist to model the different components of alcohol
use in the cycle of alcohol intake and addiction (146, 147, 154-157). Several alcohol
drinking and exposure paradigms have been developed to examine the effects of alcohol
exposure on brain chemistry, neurocircuitry, and addiction related behaviors. When
investigating the neural mechanism related to the motivational aspects of alcohol seeking
operant self-administration paradigms are commonly used. This paradigm allows the
experimenter to probe various aspects of alcohol seeking ad relapse and are sensitive to
pharmacological treatment (158-160). The effects of alcohol use can also be determined
by use of a liquid alcohol diet, known as the Lieber-DeCarli diet, which produces elevated
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blood alcohol levels. It is commonly implemented to control for nutritional intake and to
examine the effects of alcohol intake on alcoholic liver disease (161-163). Various
voluntary drinking paradigms have been established that result in stable, nondependent
levels of alcohol drinking, such as the two-bottle choice ethanol drinking procedure
(described below) (144). Additionally, Drinking in the Dark (DID) is a voluntary drinking
model used to examine binge-like alcohol consumption, as it elicits binge like alcohol
intake (>80mg/dL) (68, 164-166).
In the paragraphs below the common two-bottle choice alcohol drinking and chronic
intermittent ethanol exposure strategy used in the proceeding chapters are described.

Two-Bottle Choice Drinking
A standard, well-accepted model of alcohol intake is home-cage voluntary alcohol
drinking, whereby a rodent has free access to one bottle of alcohol and one bottle of water
over a 24-hr period, commonly referred to as two-bottle choice (2-BC) (144). This
procedure allows the animal, like a human would, to decide whether or not they will
consume alcohol. Multiple variations of the 2-BC procedure have been performed which
employ the use of differing concentrations of alcohol (e.g. 10%, 15%, 20%) provided over
varying amounts of time (e.g. 1-hr, 2-hr, 4-hr) and lasting days to months (83, 148, 154,
156, 167, 168). The use of 24-hr access to alcohol is a simple, easy model of alcohol
intake that allows for assessment of alcohol consumption after a variety of
pharmacological treatments or alcohol exposure paradigms and is a simple way to explore
the effects of alcohol on a neurochemical and molecular level (146, 156, 168).
A drawback to unlimited 24-hr access to alcohol, is it can obscure effects of shorter
acting pharmacological agents and when alcohol intake becomes physiologically relevant
in regard to blood alcohol concentration. Restricting alcohol access to short periods of
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time, e.g. 1- or 2-hr (83), is a way to get a more accurate measurement of alcohol intake
and to determine the effects of drug treatments. The need for accurate BECs after alcohol
access allows for confirmation that alcohol was consumed rather than spillage from the
bottle as a result of the rodents playing with the bottles. Additionally, if the temporal pattern
of alcohol drinking is of importance intake can be monitored using lickometers (167, 169).
Interestingly, rodents with alternating days of 24-hr access to alcohol display greater
alcohol intake (15% and 20% ethanol vol/vol) than rats and mice with continuous 24-hr
access (165, 170).

Chronic Intermittent Ethanol (CIE) Exposure (Alcohol Dependence)
Rendering animals’ alcohol (ethanol) dependent is a critical to the understanding of
molecular, genetic, and epigenetic changes as well as the behavioral responses
associated with alcohol dependence. Modeling dependence is commonly done using
alcohol vapor exposure, whereby rodents are placed in an inhalation chamber and
passively exposed to vaporized alcohol (171). This procedure provides the experimenter
with control over the duration and level of alcohol exposure experienced by the animal.
Repeated cycles of chronic, heavy alcohol vapor exposure to intoxication followed by
withdrawal leads to alcohol dependence (171). A typical chronic intermittent alcohol
exposure procedure is repeated for 4 cycles, where one cycle is comprised of a week of
Chronic Intermittent Ethanol (CIE) exposure followed by a week of test drinking, typically
2-hr/day (172).
Prior to CIE or Air exposure a baseline alcohol drinking period occurs. Mice
commonly have access to one bottle of 15% alcohol (v/v) and one bottle of water for 2-hr
in the home-cage Monday-Friday. However, other durations of access, percent alcohol or
adding sucrose or quinine to the alcohol can occur. Baseline typically lasts for 4 weeks to

14

establish stable levels of voluntary alcohol drinking. Each day immediately prior to the start
of alcohol vapor exposure, mice are injected intraperitoneal with a loading dose of alcohol
(1.6 g/kg; 8% w/v) with pyrazole, an alcohol dehydrogenase inhibitor (1 mmol/kg) in a
volume of 20 ml/kg of the mouse’s body weight. Air control mice are treated in a similar
manner but receive an injection of saline with pyrazole. Mice are placed in alcohol vapor
or air inhalation chambers for 16-hr/day for 4 days starting Monday and proceeding
through Thursday. Mice are removed from chambers Friday morning and remain abstinent
from alcohol until Monday (72-hr), where daily 2-hr access to 15% alcohol and water
resumed as in baseline (172, 173).
Following alcohol vapor exposure mice significantly escalate their alcohol intake
from baseline and compared to air exposed mice. This effect can be demonstrated after
a single cycle of alcohol exposure and withdrawal, but with multiple cycles alcohol intake
is enhanced even further (83, 157, 174). Additionally, CIE exposure has been
demonstrated to increased drinking in a 24-hr access model (175). The CIE model of
alcohol dependence not only increases alcohol intake in a free-access, home-cage
drinking models but has been demonstrated to increase alcohol intake and lever
responding in operant self-administration (176, 177). Beyond increasing alcohol intake,
chronic vapor exposure produces anxiety-like behavior, increases blood alcohol
concentrations (40), causes molecular and neurochemical changes, and is specific to
alcohol-related reward (154, 176, 178). Thus, making the CIE model of alcohol
dependence a useful paradigm to study the effects of AUD on the brain and behavior.

Current AUD Treatments
There is a lack of fully effective treatments for alcohol addiction. Briefly described
below are the main treatment strategies for AUD.
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Cognitive Behavioral Therapy (CBT)
Psychotherapy is a well-established, nonpharmacological approach to treat mental
health disorders including addiction. Cognitive behavioral therapy (CBT) is a problemfocused, action-oriented form of psychotherapy, used to target and treat specific
behavioral problems. Through CBT one recognizes cognitive distortions (biased, negative,
irrational thoughts) that contribute to a cycle of negative thoughts, feelings and behaviors.
Errors in thinking are identified and coping strategies are developed in order to challenge
the cognitive distortions in thinking, to ultimately change the behaviors that lead to alcohol
use. This is an effective treatment for substance use disorders where it has been known
to improve abstinence in alcoholics (55, 179). Cognitive behavioral therapy is effective in
treating mental health disorders that co-occur alongside AUD, such as depression and
anxiety which contribute to excessive drinking (180).

Mutual Support Groups/12-Step Programs
Mutual-support groups like Alcoholics Anonymous (A.A.) and other 12-step
programs are psychosocial support systems to improve abstinence. People meet to share
experiences in a nonjudgmental, peer-support setting to gain self-awareness of the
thoughts and behaviors that lead to substance use and the effect their use has on them
and those around them. In-patients that attended regular A.A. meetings had reduced
relapse and improved abstinence rates (181-183). Additionally, regular attendance to A.A.
was associated with less drinking over an 8- and 16-year period (36).

Pharmacological Intervention
In the treatment of AUD pharmacotherapies are highly sought after by healthcare
professionals to reduce craving, intake, and symptoms of withdrawal. Currently, only three
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medications are Food and Drug Administration (FDA) approved. Two (naltrexone and
Acamprosate) treat craving and intake of the of alcohol to improve abstinence and
disulfiram (Antabuse) which creates avoidance to alcohol through aversion. These three
compounds are briefly described below.
Disulfiram (Antibuse) has been around since 1949 and relies heavily on the
psychological aspect of maintaining abstinence, because it requires compliance to the
medication in a desire to avoid alcohol drinking. Alcohol is metabolized to acetaldehyde
by

alcohol

dehydrogenase,

acetaldehyde

is

then

metabolized

by

aldehyde

dehydrogenase to acetate. Disulfiram acts as an aldehyde dehydrogenase (ALDH)
inhibitor, causing acetaldehyde to build up in the body (184). Unlike other pharmacological
agents, Disufiram does not reduce craving or intake to maintain abstinence through a
receptor mediated mechanism. It is through fear of the negative reaction between
disulfiram and alcohol, resulting in unpleasant physical feelings (nausea, vomiting,
flushing and sweating), that causes avoidance of alcohol in the maintenance

of

abstinence (185).
Naltrexone is a competitive µ-opioid receptor (MOR) antagonist, which blocks the
effects of endogenous opioids which are increased during alcohol administration (186).
Preclinical studies blocking MOR in the VTA prevent DA release in the NAc (187) . Alcohol
activates the endogenous opioid system increasing DA in the NAc (188). By blocking
MORs, naltrexone reduces the rewarding properties of alcohol by blunting opioid receptor
mediated dopamine release within the nucleus accumbens (77, 189). Clinical studies have
revealed naltrexone decreases the urge to drink, prevented heavy drinking, reduced the
number of drinks consumed and improved abstinence (55, 77).
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Acamprosate is the third FDA approved medication for AUD and was originally
believed to act by antagonizing NDMA receptors modulating their activity (190, 191).
Chronic alcohol use enhances glutamate signaling in the brain and targeting the glutamate
system by NMDA receptor antagonists can reduce the reinforcing effects of alcohol and
treat AUD (51, 192). Evidence further supporting the role of reducing glutamate signaling
in the treatment of excessive alcohol consumption comes from studies demonstrating
reductions in mGluR5 receptors reduces the development of alcohol dependence.
Furthermore, Acamprosate had no effect in mice lacking mGluR5 (52). Acamprosate was
thought to target NMDA receptors to reduce glutamate signaling, improve abstinence,
block excessive alcohol intake (51, 190, 193). However, while the calcium salt of
Acamprosate was effective in reducing alcohol administration in rats the sodium salt of
Acamprosate was ineffective (194). This evidence indicates that the important active
moiety of Acamprosate is the calcium salt.

New, Exploratory Medications
In search for new efficacious drugs for treating AUD other brain signaling pathways
which have been shown to be involved in drug and alcohol use are being explored as
potential targets. Researchers are turning to pharmacological agents that are currently
FDA approved and established as treatments for other disorders to determine their
efficacy in the treatment AUD.
Agents targeting the noradrenergic system are being investigated as potential
medications for alcohol addiction. Prazosin and doxazosin are alpha-1 antagonists which
have been demonstrated to reduce the number of drinks per week and craving induced
by stress and cues (195, 196). The alph-2A receptor agonist guanfacine decreased
alcohol intake in high drinking rats as well as attenuating alcohol seeking and cue-induced
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reinstatement and normalized glutamatergic transmission in the mPFC that is
dysregulated by alcohol use (197).
Some alcohol related behaviors have been demonstrated to be controlled by the
opioidergic system. New compounds targeting opioid receptors have been generated and
show promise in efficacy. One such agent being investigated is nalmefene a μ- and δopioid receptor antagonist, with partial κ-opioid receptor agonism. A clinical study in
Europe revealed nalmefene was able to reduce binge drinking and alcohol intake in
dependent individuals (198).
Reducing hyperexcitability through inhibiting glutamate activity, can reduce alcohol
craving and obsessive drinking behavior (51). Potentiating GABA activity through GABA
receptor activation is another promising mechanism. Compared to placebo, the
anticonvulsant topiramate acting through agonistic action at the GABA receptor, reduced
glutamate hyperexcitability reducing alcohol craving and obsessive drinking behavior
compared to those given placebo (199).
The stimulant methylphenidate used to treat children with attention deficit
hyperactivity disorder (ADHD) increases hippocampal neurogenesis and elevates BDNF
in blood plasma (200, 201). When children with ADHD were treated for six weeks with
methylphenidate BDNF in the plasma increased significantly (200). Another study did not
find significant differences of BDNF in the plasma between healthy control children and
those with ADHD but did see a significant increase in BDNF after 8 weeks of
methylphenidate administration (202). Due to the common abuse of stimulants like
methylphenidate (203, 204) and the concern of overdoses if combined with alcohol, these
pharmacotherapies may not be suitable for the treatment of AUD.
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Described above is a sampling of medications being investigated as potential AUD
therapeutics. Although, the list of approved medications for AUD is limited and
unfortunately not efficacious in all individuals, requiring the development of new
medications and treatment strategies to improve abstinence and control alcohol intake.

Exercise
Voluntary exercise is a natural method being explored to treat neuropsychiatric,
neurodegenerative, and addiction-related disorders. The sections below describe some of
the information related to the description and benefits of exercise and the evidence
currently available that relates to exercise in the treatment of addiction.

Health Benefits
Physical activity is the movement of the body by skeletal muscles which increases
energy expenditure above basal metabolic rate (calories required for survival), measured
in kilocalories to survive (205). Exercise is a sub-category of physical activity, and the
terms are often used interchangeably (205). Although, exercise is more accurately defined
as highly structured, planned, repetitive physical activity aimed at increasing energy
expenditure, improving physical fitness, and health (205, 206). Sedentary behavior is
defined as any waking behaviors that uses ≤1.5 metabolic equivalents (MET), defined as
energy expenditure when sitting, or lying down (207).
A host of health benefits are associated with exercise. Moderate to intense exercise
is associated with reductions premature death, cardiovascular risk, cancer, type II
diabetes, and increases energy expenditure, inducing weight loss and reducing obesity
(208). Resistance exercise increases bone density, preventing bone loss and
osteoporosis (209). Exercise improves immune and anti-inflammatory function (210-212),
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reducing low-grade inflammation and increasing anti-inflammatory cytokines (213).
Improvements in cardiovascular health are noted including lowered resting pulse,
improvement of blood vessel condition, and increasing blood flow to the brain (213, 214).
Of relevance to neuropsychiatric disorders, exercise elevates brain-derived
neurotrophic factor (BDNF) (136, 137) increasing neurogenesis and the growth of dendritic
spines, reducing the loss of gray and white matter of the brain (215, 216). The
improvements to blood flow, immunity, inflammation, and neurogenesis contribute to
improved memory and cognition, and decreasing the risk of developing Alzheimer’s and
Parkinson’s disease (217, 218). Additionally, exercise improves sleep and reduces stress,
depression and anxiety, all of which exacerbate neuropsychiatric disorders, and it has
been shown to reduce drug and alcohol use and improve abstinence (219-222).

Exercise is Rewarding
Exercise is naturally rewarding to humans and animals and it is voluntarily
performed by rodents (137, 213, 223, 224). In addition, rodents will operantly respond for
a wheel (224, 225) and develop conditioned place preference (CPP) for the wheel-paired
side (226-228). Not only do mice in laboratory conditions partake in running behaviors,
even in the wild mice have been shown to voluntarily run on wheels (229). The rewarding
properties of exercise, like alcohol and other drugs of abuse, are mediated via the
mesolimbic reward pathway (226). This makes rodent models for investigating the use of
exercise in the treatment of excessive alcohol intake feasible.

Exercise as a Treatment for Alcohol Use Disorder
Exercise intervention is being used and investigated as a natural adjunct in the
treatment of drug and alcohol use, as it targets brain systems implicated throughout the
stages of addiction and has demonstrated the ability to assist in the prevention of drug
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and alcohol abuse and to improve abstinence (230, 231). The naturally rewarding nature
of exercise makes it an option as an alternative, nonpharmacological reinforcer to alcohol,
reducing the potential of abuse and addiction (223, 232-234).
Unfortunately, there is dearth of literature surrounding the effects of exercise on
alcohol intake in preclinical animal models. The existing studies have not focused on the
effect of exercise in dependence states, but rather on the effects of exercise on
nondependent alcohol drinking. The majority of these studies allowed unlimited wheel
running in the home cage for 2 to 3 weeks with concurrent 24-hr access to 10% alcohol.
They demonstrated a reduction in alcohol consumption only in female mice with no change
in alcohol metabolism or food consumption (136, 138, 139, 223). One caveat to these
studies is the concurrent unlimited access to both the running wheel and alcohol, these
are competing behaviors which cannot be performed simultaneously. When looking at the
studies where alcohol drinking and wheel running were performed at different times the
results vary.
Alternating weeks of wheel running in the presence or absence of alcohol (10%
ethanol) did not affect subsequent alcohol consumption in male C57BL/6J mice (235).
Additionally, a study conducted using 11 days of running did not alter binge-like alcohol
drinking in the drinking in the dark paradigm in mice (136). Complicating matters further,
when wheel access was provided during a 1- or 2-week alcohol withdrawal period,
subsequent alcohol consumption was increased in rats that exercised during withdrawal
(236). The variability of these results is most likely due to the different methodologies used.
Although all of the studies allowed unlimited running wheel access and alcohol was
provided 24-hr/day, the animal’s sex and species, the number of days of running, and the
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history of behavioral experience are different across the different results. Additionally, as
mentioned previously these studies do not address alcohol dependence related drinking.
The efficacy of exercise in human alcohol abuse and addiction has been
demonstrated in the literature. When adolescents and young adults participated in team
sports of regular physical activity, they were shown to be less likely to smoke, drink
alcohol, or use drugs (231, 237-239). In detoxified alcoholics, acute exercise at a low and
moderate intensity reduced the urge to drink alcohol and reduced the amount of alcohol
consumed (239, 240). Abstinence outcomes were improved when patients participated in
treatment programs that involved exercise (241-244). Interestingly, in nonalcoholic,
healthy adults multiple form of exercise have been demonstrated to cause increases in
alcohol intake (245-247).

Although an increase in nondependent drinking is seen,

exercise blunts the development of alcohol abuse and dependence (231, 243).
Exercise has been demonstrated to reduce the administration of a variety of drugs
and therefore by examining these studies we can further verify the ability of exercise to
modulate excessive drug intake and provide insight into the neurological mechanisms for
this effect. For example, wheel running attenuated acquisition of nicotine selfadministration (248) and methamphetamine self-administration was reduced when rats
had concurrent access to a running wheel (249). Nonconcurrent treadmill and wheel
running reduced the self-administration of cocaine, heroin, and morphine in male and
female rats (250-254). The ability of exercise to attenuate drug administration is not limited
to aerobic exercise. Weighted vests were attached to rats to simulate resistance training
revealed a reduction in self-administration of i.v. cocaine and heroin (255, 256).
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Brain-Derived Neurotrophic Factor (BDNF)
Background
The focus of the work provided in the proceeding chapters involves the role of brainderived neurotrophic factor (BDNF) in alcohol addiction and exercise. As a member of the
neurotrophin family along with nerve growth factor (193), neurotrophin-3 (NT-3), and
neurotrophin-4 (NT-4), BDNF plays an important role in the brain. It is highly involved in
synaptic plasticity, differentiation and survival of neurons, and the growth and
maintenance of dendrites and dendritic spines (257). Multiple lines of research have
revealed a critical role for BDNF in learning, memory (258), addiction, neuropsychiatric
disorders, and neurodegenerative diseases (257).
Mitochondrial dysfunction is a common pathology associated with degenerative
brain disease and can be suppressed by BDNF in models of neurodegeneration (259).
The neuroprotective function of BDNF is demonstrated in animal models of Huntington’s
disease, where BDNF reductions lead to cell death and recovery of BDNF levels protects
against neuronal loss (260).
Expressed throughout the brain, BDNF is found in all cell types including neurons,
astrocytes, oligodendrocytes, and microglia, with the greatest expression being in the
hippocampus and cortex (257, 261). Transcription of Bdnf mRNA commonly occurs in an
activity dependent fashion through an influx of calcium (Ca2+) through voltage gated
calcium channels or NMDA receptors (262). While the hippocampus is a major producer
of BDNF the majority of striatal BDNF protein originates in the cortex, with the remainder
coming from the substantia nigra (263, 264). However, the hippocampus does project to
the infralimbic mPFC where hippocampal BDNF facilitates fear extinction (46).
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Trafficking of BDNF in neurons is extremely important to neuronal survival. For
example, in Huntington’s disease polyglutamate (ployQ) expansions in huntingtin (Htt)
causes protein misfolding, leading to aggregation of the protein (260). Transport of BDNFcontaining vesicles from the frontal cortex to the striatum is mediated by Htt interacting
with molecular machinery that transport vesicles along microtubules to the synapse for
release (265, 266). The polyQ mutation in Htt causes aggregation of Htt, preventing proper
interaction with microtubule trafficking machinery inhibiting BDNF transport (260). Lack of
BDNF in corticostratial synapses results in a loss of LTP and the protective effects of the
striatum on regulating alcohol intake (267-269).
Mature BDNF protein is translated from mRNA into the precursor protein,
preproBDNF, in the endoplasmic reticulum. This form of BDNF is cleaved into proBDNF
which is packaged into secretory vesicles in the Golgi where it is either released from the
synapse or further processed to mature BDNF (mBDNF) before being released (270).
Experiments fusing green fluorescence protein (GFP) to BDNF illustrate the packaging of
BDNF into vesicles at the Golgi, which are then transported throughout the neuron,
frequently co-localized to PSD-95, which is commonly associated with NMDA receptors
at excitatory synapses (271).
When BDNF is released from synapses it binds to its main receptor tropomyosin
receptor kinase B (TrkB), where it causes the receptor to dimerize and autophosphorylate
the intracellular tyrosine domain activating one of three signaling cascades (272).
Phosphorylation of TrkB recruits Shc which can activate signaling through either the PI3K
pathway or the MAP kinase pathway, inducing pro-survival and pro-differentiation genes
(272). Activation of TrkB by BDNF can stimulate PLCgamma, increasing IP3, Ca2+, and
PKC activity increasing synaptic plasticity and gene transcription (272) and can induce
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expression of BDNF itself in a positive feedback mechanism (273). The BDNF-TrkB
complex is internalized through endocytotic vesicles, forming a signaling endosome that
is transported through the neuron to the needed location inducing gene transcription and
other cellular responses (272). Differential splicing of exons that encode parts of the
intracellular catalytic domain of TrKB have been shown to produce a truncated TrkB
isoform that does not possess the kinase domain, where it controls neurotrophin signaling
and regulation of intracellular Ca2+ release through IP3 pathway (272, 274).
In addition to activating TrkB, mBDNF and proBDNF can bind to p75NTR, a member
of the tumor necrosis receptor family, with low- and high-affinity respectively. Signaling of
p74NTR leads to activation of pro-apoptotic effects via Jun kinase or conversely prosurvival via NF-kB pathways (272, 275).

Exon Variants
Located on chromosome 11 the Bdnf gene is complicated in its structure. Originally
thought to be comprised of four exon variants (276) it was later determined that the rat
gene contained 9 unique exons and the human 11 (257). Eight of the exons are 5’
upstream noncoding, promoter sequences. They are each spliced to Bdnf exon IX, which
encodes the BDNF protein, generating 11 variants all capable of producing the functional
protein (257). Adding further complexity, a short- and long-3’UTR exist which additionally
aid in mRNA trafficking and expressional control through microRNA regulation (257).
The function of multiple exon variants is two-fold: 1. They act as unique promoter
regions requiring specific transcription factors (257), and 2. They are involved in the
trafficking of Bdnf mRNA to specific neuronal regions for localized protein translation (277,
278). The majority of Bdnf mRNA found in the brain are variants containing exons I, II, IV,
and VI (257, 279). Variants are expressed to different degrees in different regions of the
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brain. For example, Bdnf exon I, IV, and VI are highly expressed in the amygdala. In the
cerebellum and medulla all variants apart from exons V and VII were detected with exon
II being expressed the most here than in other regions (279). In the hypothalamus exon I
and II contributed the most to total BDNF protein, where in the PFC and HPC exon IV and
VI were the dominant sources (261).
In cultured neurons Bdnf mRNA I, II, IV, and VI were found in the soma and proximal
dendrites. When the neurons were stimulated exons II and VI had been trafficked to the
distal dendrites with exon I and IV staying in the soma an proximal dendrites (277, 280).
To confirm a functional, morphological role of the Bdnf mRNA exon variants, siRNA
technology was used to silence the different Bdnf mRNA variants (278). Knocking down
Bdnf exons I and IV resulted in reduced dendritic crossings at 30µm but had no effect
beyond 60µm. Conversely, silencing exons II and IV with siRNA reduced dendritic
crossings at 90µm (278). In addition, they also found neurons overexpressing exons I and
IV increased TrkB phosphorylation, a sign of BDNF-TrkB activation, at receptors proximal
to the soma, and exons II and IV activated receptors at much more remote distances.
These data provide evidence that trafficked exon variants have a functional role in TrkB
receptor activation and dendritic morphology.
Exon variants appear to play a role in the expression of other Bdnf exons. For
instance, when exon I was genetically deleted exons II, IV and VI, along with BDNF protein
were reduced in the hypothalamus (261). Similarly, when exon IV was removed exon II,
exon VI, and protein levels decreased. Conversely, knocking out exon I in the PFC caused
an increase in exon II and IV expression, with no reduction in protein. However, knockout
of exon IV in the PFC did not affect other transcript variants, but protein was reduced.
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Interestingly, in the HPC exon I removal increased exon IV expression and showed
no reduction of protein. When exon IV is eliminated both exon I mRNA and total protein
are reduced [250]. This work demonstrates a region specific, complex relationship
between exon variants and protein. It provides evidence that a redundancy mechanism
may exist to mitigate loss in BDNF protein. Furthermore, loss of BDNF protein from
knockout of exon IV and VI, but not I and II, caused significant impairments in PFC
GABAergic interneuron markers (261). Mice with genetic knockout of exon IV have
impaired inhibitory transmission from GABAergic neurons to layer V pyramidal neurons of
the PFC (281).
Mice with either Bdnf exon I or II genetically disrupted exhibit increased serotonin
transporter expression in the PFC, HPC, and hypothalamus (HYP) [250], enhancing
serotonin reuptake from the synapse. These mice display increased aggression
associated with serotonin deficits in the PFC (282). Interestingly, mice deficient in exon IV
or VI did not exhibit behavioral abnormalities. This demonstrates a role of specific Bdnf
mRNA exon variants in behavior.
In human Bdnf exon II, a valine (Val) to methionine (Met) polymorphism at residue
66 is known to occur. The Met variant impairs the transport and vesicular secretion of
BDNF protein, restricting BDNF to the cells body and lowering BDNF in blood plasma
(283, 284). The polymorphism is associated with increased risk of neuropsychiatric
disorders such as major depressive disorder [274], bipolar (285, 286), increased cognitive
impairment in Parkinson’s disease (287), Alzheimer’s disease (288), memory impairment
(289), and is linked to early onset of alcohol abuse (290-293).
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Additional Regulatory Control of BDNF Expression
Epigenetic modifications regulating BDNF protein expression are implicated in
neuropsychiatric disorders (294). Acetylation and deacetylation of histones affect ability of
chromatin to compact or relax compacting, reducing or enhancing gene transcription
respectively, is one such epigenetic modification (295). Deficits in histone H3 acetylation,
specifically at Bdnf I and IV, are associated with reduced BDNF protein expression and
blocking histone deacetylation by treatment with HDAC inhibitor trichostatin A (TSA)
elevates BDNF protein levels (296, 297). Additionally, it has been proven that the
endogenous HDAC inhibitor beta-hydroxybutyrate, like its synthetic analogue sodium
butyrate, act to inhibit histone deacetylation increasing BDNF expression (298, 299).
Another component to mRNA transcription control is binding of transcription factors
to promoter sequences on the DNA, whereby additional factors can be recruited and
complexed together allowing for the activation of RNA polymerase for transcription (191).
As previously stated, one role of the various Bdnf mRNA exon transcripts is to serve as
unique promoter sequences for the transcription of Bdnf mRNA, ultimately to produce
active BDNF protein encoded by exon IX (257). Most of the investigation into the
transcription factor binding sites regulating Bdnf mRNA expression has focused on exon
IV, with several studies evidencing transcription factors which bind to exon I (300-302).
The various Bdnf mRNA exons have been demonstrated to be under unique
transcriptional control. For example, while both exon I and IV are expressed in an activity
dependent manner the factors that are critical for their expression are different (303).
Luciferase assay showed mutation of the CREB site did not significantly affect activitydependent transcription of exon I, whereas it is critical for exon IV expression (303). While
USF1/2 can bind to sites on exon I and exon IV it appears to only play a role in activity
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dependent transcription of exon IV as induced by KCl depolarization (303). A dominantnegative form of AP-1 was demonstrated to be critical in the expression of Bdnf I but not
for exon IV mRNA (273). The same transcription factor can be involved in the transcription
of several Bdnf mRNA exon variants. For example, the ARNT2-NPAS4 dimer was
confirmed to be involved in the transcription of both exon I and IV (300, 303). For example,
MEF2 was initially reported to activate transcription of exon I (304), later it was revealed
to bind to a site on exon IV (305). In addition to transcriptional activation, it has been shown
that exons I and II possess a neuronal restrictive silencer element (NRSE) that is
repressed by repressor element-1 silencing transcription factor (REST) (302). Another
difference in transcriptional control is seen in exon VI where a glucocorticoid-responsive
element is influenced by corticosterone (306) and two forms of CaMKII specifically activate
exon IV (307).
Methylation of DNA is another mechanism regulating Bdnf mRNA transcription. DNA
methyltransferase (DNMT) methylates the CpG islands in Bdnf IV (308). Methylation
allows for the binding of the methyl binding domain (MBD) protein MeCP2, to the
methylated region of the DNA recruiting repressor proteins (309, 310).
The BDNF single nucleotide polymorphism (SNP) at position 196 of Bdnf II, a valine
to methionine mutation at codon 66 (Val66Met) occurs is associated with impaired
trafficking and release of BDNF protein and dysregulated dopaminergic functioning (311,
312). Healthy human adults with the Val66Met variant consumed higher levels of alcohol,
had earlier onset of alcohol dependence, and had accelerated relapse to alcohol drinking
than Val66Val (290, 293, 313). In the monetary incentive delay task Met carriers had
greater BOLD response than Val in the striatum during reward anticipation, which was a
predictor of greater alcohol intake (40). A mutant mouse was generated containing a
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human Val66Met variant exhibited compulsive, excessive alcohol drinking. When the wild
type Val variant was expressed in the mPFC of these mice, alcohol intake was dramatically
reduced (314).

BDNF in Alcohol Use
A strong inverse relationship exists between alcohol use and BDNF protein levels
throughout the brain and human alcoholics have demonstrated low BDNF protein levels
in blood (315, 316). The use of preclinical animal models has directly linked reductions in
BDNF protein have to escalated alcohol intake, and by increasing or replenishing BDNF
protein in the brain escalated alcohol intake can be prevented or reduced (174, 317). An
overall reduction of BDNF in the brain is associated with increased alcohol intake,
demonstrated by transgenic mice with BDNF protein deficiencies (317-319). As well,
systemic inhibition of BDNF-TrkB signaling caused increased alcohol intake and globally
upregulating BDNF-TrkB activity reduced alcohol consumption (317, 320).
Although global upregulation of BDNF is associated with reduced alcohol intake and
reductions with increased intake, further examination illustrates brain regional differences.
For example, in alcohol preferring P-rats, that exhibit high levels of voluntary alcohol
intake, Bdnf mRNA and protein were found to be reduced in the CeA and MeA but not in
the BLA (321). Moreover, P-rats display higher HDAC2 activity which corresponds to
reduced acetylated histone H3 and has been demonstrated to reduce Bdnf mRNA
transcription. Acute administration of alcohol decreased HDAC activity in the CeA,
increasing Bdnf mRNA expression and attenuating anxiety-like behavior (298, 322).
Further demonstrating the role of reduced BDNF in the CeA to increase alcohol intake,
infusion of Bdnf mRNA antisense oligodeoxynucleotides (ODNs) into the CeA caused rats
to consume more alcohol (323). These data may allude to a potential mechanism in some
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individuals that drives increased drinking, as a way to alleviate anxiety by increasing
alcohol intake to elevate BDNF within the CeA and MeA.
For BDNF to affect downstream signaling it must bind and activate the TrkB
receptor. It was found that following 7 weeks of CIE exposure the TrkB receptors in the
hippocampus but not mPFC demonstrated increased phosphorylation compared to
controls 3-hr into acute withdrawal which returned to control levels after 3 weeks of
abstinence (324). Total TrkB expression was found to not be altered by CIE exposure in
the hippocampus, whereas the mPFC demonstrated increased total TrkB protein
expression during acute withdrawal but not protracted abstinence (324). Thus, these data
reveal a potential role of the BDNF-TrkB system in the hippocampus during early alcohol
withdrawal.

BDNF in the Brain (mPFC and Striatum)
The medial prefrontal cortex (mPFC) is critical in top-down cognitive control of
executive behavior and in addiction (104, 105). Several studies exposing rodents to
alcohol have demonstrated a reduction in Bdnf mRNA and protein within the mPFC.
Chronic alcohol vapor exposure reduced Bdnf mRNA and protein in rodents measured
proximal to alcohol vapor exposure and after prolonged alcohol withdrawal (178, 325,
326). Even in models of voluntary drinking, including 14 days of operant self-administration
or 6 weeks of home-cage drinking, Bdnf mRNA was diminished in the mPFC (327, 328).
This reduction of BDNF in the mPFC appears to be involved with alcohol drinking behavior.
This effect was demonstrated by direct infusion of BDNF protein into the mPFC of mice
rendered alcohol dependent by chronic vapor exposure that attenuated the escalated
alcohol intake (174). Moreover, using viral-mediated overexpression of BDNF in the
mPFC, CIE-induced escalated alcohol intake was prevented (174). One mechanism for
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the reduction of BDNF seen in the mPFC after alcohol exposure is through enhanced miR206 expression. MiR-206 is a negative repressor of Bdnf mRNA and was revealed to be
elevated in the mPFC of rats even after 3 weeks of alcohol withdrawal (325, 326). Operant
self-administration for alcohol was enhanced when miR-206 was virally overexpressed in
the mPFC of nondependent rats (325).
Alcohol has opposite effects on BDNF protein expression in the striatum versus the
mPFC. In the cortex alcohol causes a reduction in the expression of BDNF, whereas in
the striatum BDNF is elevated. Further complicating matters, the striatum is divided into
multiple sub-regions, in which BDNF demonstrates opposing functions. The sub-regions
include dorsolateral striatum (DLS), dorsomedial striatum (DMS), and ventral striatum
(329) which contains the nucleus accumbens (97). Majority of the work looking at the role
of BDNF in the striatum has focused on the DLS and NAc and has revealed opposing
functions of the dorsal and ventral striatum.
The DMS is involved in goal-directed behaviors that may influence alcohol seeking
(330). Alcohol intake was not affected when BDNF protein was infused in this region (331).
However, the NAc, also implicated in goal-directed behavior, shows an increase in BDNF
levels after alcohol exposure, an opposite effect to the mPFC. This was demonstrated in
rats 3 weeks after chronic alcohol exposure

(325). This effect is not restricted to

prolonged, heavy alcohol exposure. Both voluntary 2-bottle choice and operant selfadministration

increased

BDNF

protein

expression

in

the

NAc

(327,

332).

Pharmacologically inactivating the TrkB receptor, with ANA-12, prevented increased
alcohol intake in both 2-bottle choice and a model of binge drinking (332).
One mechanism through which BDNF in the NAc may enhance alcohol intake is
through increasing dopamine receptor 3 (D3R) expression. Pharmacological inhibition and
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genetic knockout of D3R decreased alcohol intake in mice (332). The release of BDNF
protein from cortical neurons has been shown to increase the expression of D3R in the
NAc and when TrkB is pharmacologically inactivated a reduction in D3R expression was
detected (332, 333).
The DLS takes on a distinct role to that of the DMS and VS, being involved in
controlling compulsive, habit-like behavior (334, 335). In rodents a single administration
of low-dose alcohol, either voluntary 24-hr access two-bottle choice drinking paradigm or
acute injection, increased BDNF expression in the DLS (268, 317, 336). Further
supporting the positive association between alcohol and BDNF in the striatum, striatal
primary neurons treated with acute alcohol increased BDNF expression and release (268).
Operant self-administration of alcohol resulted in increased Bdnf mRNA in the DLS (331).
Regulation of dorsal striatal BDNF may be regulated in part by reductions in miR-124a, a
negative regulator of Bdnf mRNA in the dorsal lateral striatum (336). Alcohol elevates
BDNF in the DLS which activates MAP kinase signaling, resulting in increased
transcription of DRD3 and dynorphin, which is required to reduce alcohol intake (268,
317, 320). Repeated bouts of alcohol intoxication reduced levels of cortical BDNF, which
is trafficked to the DLS, additionally BDNF in the DLS becomes less effective at preventing
excessive alcohol drinking (328). The DLS plays a key role in the formation of compulsive,
habit-like behaviors (337) and as prefrontal BDNF decreases and BDNF generated within
the dorsal striatum increases, a shift from recreational to uncontrollable, compulsive use
may occur.

BDNF and Exercise
It is well known from research in humans and animals that wheel running (exercise)
is able to increase BDNF (mRNA and protein) levels throughout the brain. Much of the
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research has focused on the effect of aerobic exercise to increase BDNF in the
hippocampus, primarily the dentate gyrus sub-region.
Several weeks of voluntary wheel running will increase BDNF in the HPC and PFC
of mice and rats (136, 137, 298, 338). Even a single session of wheel running in rats has
been shown to increase hippocampal BDNF levels (339, 340). Rats which were trained to
run for 3 days had increased Bdnf mRNA levels in the HPC after a 6- or 12-hr running
session 10 days following the training period (341). In a study exploring how often exercise
must be performed in rats to elevate BDNF protein in the brain, 4 weeks of continuous 24hr wheel access significantly elevated BDNF protein in the HPC, and increases were
maintained even after 90 days of running (137). This study further demonstrated that
BDNF protein was elevated in the HPC when running occurred on alternating days,
however it took 21 days to see significant increases. It took 2 weeks of no running to see
BDNF protein levels return to baseline in mice with continuous access to a running wheel,
those with alternating days of running saw BDNF levels decay in 1 week. Interestingly,
exercise appears to prime the BDNF system. Where it takes 2 weeks to see increased
BDNF expression in the brain, rats with a history of running were able to robustly increase
BDNF levels with a single bout of running after 1 and 2 weeks of sedentary behavior (137).
Another form of aerobic exercise training in rodents is forced treadmill running. This
paradigm allows for enhanced control over the time and intensity of the aerobic exercise
and will increase BDNF in the brain (342). One consideration is the intensity of the exercise
and duration must be carefully chosen, as too fast of speed or too long of a training session
can induce stress in the rodent and suppress BDNF expression and elevate
corticosterone, which could confound the interpretation of the data (342, 343). It has been
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found that 3 weeks of forced treadmill running, 30-min/day, was sufficient to increase
BDNF immunopositive cells in the cortex and striatum of rats (344).
The ability of exercise to increase BDNF is not restricted to rodents. Both resistance
training and endurance exercise increases BDNF levels in humans (345, 346). Peripheral
BDNF, measured in the blood, comes primarily from the brain and can cross the blood
brain barrier (BBB) in both directions (347). It has been found that humans who performed
4-hr of rowing exercise had increased blood BDNF, with approximately 75% of the BDNF
coming from the brain determined by calculating the concentration difference between
BDNF concentrations measured from blood collected from the jugular vein and brachial
artery (347-349). Acute, moderate exercise (30 min/day) increased BDNF in the blood of
humans, an effect that declined 60 minutes after exercise (350, 351). Three months of
cardiovascular endurance exercise, performed for 60 min/day, elevated BDNF levels in
the blood of humans (349). Even in trained athletes, serum BDNF was elevated following
a brief exercise session to exhaustion (352). Overall, exercise in general increases BDNF
levels, with the intensity or duration of exercise not increasing the intensity or duration of
exercise does not further increase BDNF levels in the blood of healthy men (353).

Mechanisms for Exercise Induced BDNF Expression
Beta-hydroxybutyrate
Ketone bodies such as beta-hydroxybutryate (βOHB) and acetoacetate are
produced primarily in the liver during intermittent fasting, starvation, high fat diets e.g.
ketogenic diet, and exercise (298, 354). In hepatic cells mitochondrial β-oxidation
metabolizes fatty acids to acetyl-CoA, which is then converted to βOHB by βhydroxybutyrate dehydrogenase (BDH1). The liver shuttles βOHB in to the blood stream
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through SLC16A6 channels and crosses the blood brain barrier (BBB) via monocarboxylic
acid transporters (MCT1/MCT2) (354, 355).
Ketone bodies have neuroprotective effects in models of neurodegenerative
diseases, which are suggested to be the result of epigenetic modifications of histones and
receptor signaling (354, 356). Histone acetylation is one mechanism which controls the
expression of Bdnf mRNA (297, 357). Histone deacetylases (HDACs) remove acetyl
groups from histones decreasing gene transcription and can be inhibited by βOHB (358).
It is established that HDAC inhibitors such as SAHA and trichostatin A (TSA), can induce
BDNF expression (297, 298). Exercise has been demonstrated to increase βOHB which
inhibits HDAC activity and increase Bdnf mRNA and protein expression (298, 359).
In addition to endogenous HDAC inhibition, βOHB can enhance histone acetylation
by histone acetyltransferase (HAT). The lysine residue on the N-terminal tail of histones
can be modified by the addition of βOHB which recruits HATs to enhance gene
transcription (360). Furthermore, βOHB once in the brain can be converted to acetyl-CoA,
increasing the amount of substrate which can be used by HATs to acetylate histones
(354).

FNDC5/Irisin
The transcription co-activator PPAR-γ coactivator-1-alpha (PGC-1α) is derived in
areas of high oxidative metabolism e.g. skeletal muscle, brain, cardiac muscle, and liver
and reductions in the brain are associated with neurodegeneration (361). The interaction
of PGC-1α with PPAR-γ mediates gene transcription and increases in fibronectin type III
domain containing 5 (FNDC5) in muscle and brain (329, 362). Exercise induces cleavage
of FNDC5 into irisin, which is secreted into the blood, increasing Bdnf mRNA and protein
expression (329, 363). Irisin is not only generated in the brain but peripherally generated
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irisin can cross the blood brain barrier (213). Rats exposed to 8 weeks of treadmill running
increased PGC-1α mRNA expression in the frontal lobe and hippocampus (364). Even as
little as one 3-hr endurance swim session increased PGC-1α in rat muscle (365).
Correlating with increased PGC-1α levels, exercise increases FNDC5 mRNA in the brain
of rodents (213, 329). In human plasma elevated levels of PGC1A mRNA was detected
after acute or prolonged exercise (366). Studies involving humans have confirmed the
correlation between an increase in FNDC5 and irisin in the blood after exercise (367, 368).

Other Neurobiological Molecules Affected by Exercise and Alcohol
Exercise and alcohol use modulate the expression multiple molecules including
catecholamines and endogenous opioids. In the next section a selection of these
molecules is briefly discussed relating the effect of alcohol and exercise on their
expression and the role they have in BDNF expression.

Dopamine
Both drugs of abuse and exercise activate the reward pathway to affect the release
of dopamine. The dopaminergic system is comprised of the nigrostriatal and mesolimbic
pathways, which include the substantia nigra (SN) and ventral tegmental area (VTA),
regions in which dopamine (DA) is mainly synthesized from the amino acids phenylalanine
and tyrosine. The dopaminergic system is highly involved in reward, aversion, and the
regulation of mood. Dopaminergic afferents project from the VTA and SN to brain regions
including the dorsal striatum, nucleus accumbens and prefrontal cortex (75, 369-371).
Drugs of abuse have been revealed to cause adaptations of dopaminergic function
in the brain. Acute alcohol exposure enhances dopamine and chronic exposure leads to
hypofunction of the mesolimbic system with decreased DA release, driving craving and
relapse (2, 70, 75). The role of DA in the alcohol drinking behavior is illustrated by studies
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showing administration of alcohol increases the release of DA in rodents and humans (50,
372, 373). Administration of DA receptor agonists and antagonists modulate alcohol intake
and preference (374).
In contrast, exercise produces a hyperdopaminergic state, increasing DA
concentrations and DA receptor binding (226, 370). The enhancement of DA transmission
by exercise, is demonstrated to be a mechanism in which exercise can improve sleep and
reduce stress (375). Stress vulnerability in rodents and humans is associated with reduced
expression of dopamine receptor 2 (DRD2) (376, 377). Exercise may be able to reduce
stress through the enhancement of striatal DRD2 expression, as exercise has been
demonstrated to increases DRD2 (inhibitory) in medium spiny neurons in the striatum
(378, 379).
Not only has exercise been shown to regulate dopamine receptor expression, but it
increases tyrosine hydroxylase, an important enzyme in the synthesis of DA (226, 379).
Dopaminergic activity may be further modulated by exercise through the reductions in
adenosine receptors which act antagonistically to DA receptors (378). Furthermore,
exercise can increase dopamine through increasing delta opioid receptor mRNA in the
NAc, which has been demonstrated to increase DA release in this region (226).
Dopamine signaling is implicated in elevating BDNF levels in the brain. Incubation
of striatal and hippocampal tissue slices with dopamine increased BDNF expression in a
time and dose-dependent manner (380). Further confirming the role of dopamine in BDNF
expression, striatal tissue slices treated with D1 receptor agonist SKF38393 increased
BDNF protein and TrkB surface expression in the striatum (380-382). This effect was also
seen in the striatum, where SKF38393 injections in rat pups increased phosphorylated
TrkB receptors (383). In vivo treatment for 7 days with rotigotine, a dopamine agonist that
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targets all dopamine receptors, increased BDNF protein in the hippocampus and cortex
(384). Dopamine induced increases of BDNF protein are not restricted to neuron.
Administration of DA increased the production of BDNF protein in astrocytes (385, 386).
Dopamine signaling via D1DR activation may mediate the increased production of BDNF
through a cAMP/PKA/CREB signaling mechanism (387).
Not only does DA influence BDNF expression, but data exist revealing a role of
BDNF to regulate dopamine receptor expression and therefore dopaminergic activity. For
example, cultured cells treated with BDNF increased D1DR mRNA and protein, mediated
via the PI3K signaling pathway (388). In cultured astrocytes, application of BDNF
increased D5 receptor mRNA expression (389). Furthermore, when the BDNF scavenger
TrkB-IgG was administered in vivo in rats reduced D3 receptor mRNA (333).

Glutamate
Functioning as the major CNS excitatory neurotransmitter, glutamate is a
nonessential amino acid which can be synthesized from α-ketoglutarate and glutamine
(390). It is released from the presynaptic neuron and binds to its target receptors on the
postsynaptic neuron inducing excitation (390). Glutamate binds to the ion channel
receptors N-methyl-D-aspartate (NMDA), AMPA and kainate, as well as the metabotropic
family of glutamate receptors (mGluR) (391).
Glutamate is well-known to be involved in the reinforcing properties of alcohol, and
administration of alcohol reduces glutamate release and suppresses glutamatergic activity
in the nucleus accumbens (192, 392). In the CeA, acute alcohol suppresses glutamate
signaling, but chronic alcohol exposure enhances glutamatergic signaling (51, 392).
Likewise, in the striatum, chronic alcohol exposure increases glutamate, contributing to
striatal dysregulation seen in addiction (393). The role of glutamate in alcohol intake can
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be further demonstrated in rat strains which consume different amounts of alcohol. For
example, Lewis rats have lower baseline levels of glutamate in the PFC at baseline and
self-administer more alcohol than Fisher rats (394).
Acute alcohol application to rat PFC neurons inhibits NMDA receptor activity (105).
In response to NMDA receptor inhibition by alcohol, NMDA receptor mRNA expression is
increased (395). The increase in NMDA receptor expression from chronic alcohol abuse
contributes to glutamatergic hyperexcitability during withdrawal, which contributes to
alcohol withdrawal syndrome. The effects of acute alcohol have been mimicked by using
NMDA receptor antagonists (192). Alcohol alters function of NMDA receptors by directly
inhibiting the flow of ions through the receptor (396), as well as affecting the function of
mGluR5 (52). The role of glutamate receptors in alcohol drinking, seeking, relapse, and
reward have been further confirmed using the NMDA receptor antagonist Acamprosate
(185) and mGluR5 antagonist MPEP (52), where they blocked increased glutamatergic
signaling, reducing drug seeking and relapse.
Exercise has been determined to modulate glutamatergic transmission through
altering glutamate and glutamate receptor expression and function. In addition, changes
in glutamatergic signaling can regulate expression of BDNF. For example, in humans,
magnetic resonance spectroscopy (MRS) revealed an increase in glutamate in the frontal
and visual cortex following exercise (397). Exercise increases phosphorylation of Ser845
on the C-terminal tail of GluR1, which induces peri-synaptic insertion of AMPA receptors,
contributing to increased glutamate signaling and down-stream activation of kinases (398).
In mice, exercise increased AMPA GluR1 and GluR2/3 receptor subunits in the frontal
cortex and increased phosphorylation of NR1 and NR2B subunits of the NDMA receptor.
Treatment with MK801 revealed increased binding to NMDA receptor channels, indicating
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an increase in open NMDA receptors and therefore, enhanced glutamatergic signaling
(399). Treadmill running exerts a neuroprotective effect by reducing the expression of
mGluR5 and NR2B receptors and the release of glutamate in the striatum of rats (400). In
rats that underwent daily bouts of endurance exercise, in this case swimming, an increase
in muscle glucose transporter isoform GLUT4 was detected (365). The reduction in
glutamate may be as a result of increased clearance from the synapse, through increased
transporter expression and increased mitochondrial oxitdation of glutamate (401).
Increased glutamate clearance and decreased receptor expression would reduce hyperglutamatergic signaling reducing excitatory neurotoxicity and may assist in prolonging
abstinence.
Positive modulation of AMPA receptors increased Bdnf mRNA and protein
expression in vivo and ex vivo in HPC slices and in primary cortical neurons (402, 403).
Additionally, it has been demonstrated that blocking NDMA receptors in the hippocampus
attenuated elevations in Bdnf mRNA engendered by voluntary exercise in rats (404). It is
proposed that AMPA receptor activation by glutamate increases cAMP response element
binding (CREB) protein activity via MAPK and CaM-kinase phosphorylation (405). As
previously described in the Introduction, CREB activation can drive expression of BDNF.
Therefore, glutamate-mediated enhancement of CREB activity can lead to an increase in
BDNF expression (303, 340).

Norepinephrine
Norepinephrine (NE) is synthesized from dopamine in synaptic vesicles of the locus
coeruleus, which innervate cortical and limbic regions such as the prefrontal cortex and
amygdala modulating attention, executive function and which become hyperactive during
withdrawal and stress (75, 406). Excessive activation of these neurons is linked to alcohol-
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drinking behaviors and relapse (407, 408). For example, inhibiting NE synthesis reduced
voluntary alcohol drinking (409) and increasing NE release with yohimbine causes
reinstatement of alcohol drinking in human and animal models (410, 411). Data obtained
from rats provides evidence that physical exercise increases the expression of NE in
multiple brain regions, including HPC, LC, CeA and MeA (412, 413). Rats forced to
exercise using a treadmill had elevated levels of NE in the hypothalamus and prevented
immobilization stress-induced reductions of NE in the AMG and LC (414). Voluntarily
wheel running or forced running on a treadmill for 60 min/day for 8 weeks increased
expression of NE in noradrenergic cells bodies in the brain of rats (415).
Following acute and chronic aerobic exercise there is activation of noradrenergic
neurons, increasing NE in the brain and blood of humans (416, 417). Resistance exercise
has also been demonstrated to increase NE levels. Resistance trained humans at rest
were not found to have elevated NE levels compared to nontrained people. However, in
preparation for exercise plasma levels of NE where determined to be higher 30 minutes
prior to exercise, suggesting the anticipation of the exercise increases NE levels (418).
There exists a strong causal link between elevated NE expression and increased
BDNF expression. Stimulation of the vagus nerve results in an increase of NE and BDNF
in the mPFC of rats (419). Cultured hippocampal cells treated with NE increased the
release of BDNF (420, 421). Further, inhibiting the beta-adrenoreceptor with the
antagonist propranolol or DSP-4 blocked increased Bdnf mRNA transcription in exercised
rats (412, 413). Inhibiting the reuptake of NE by blocking NE reuptake transporter with
reboxetine, increased Bdnf mRNA in rats that did not exercise, this response was further
enhanced in exercising rats (422). Reboxetine treatment increased TrkB phosphorylation,
an indicator of increased TrkB activation (423). However, a NCBI PubMed search found
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no experimental studies examining the effect of reboxetine on alcohol intake in humans
or rodents. It is proposed that exercise increases NE levels, thereby enhancing activation
the beta-adrenoreceptor which, in turn, increases the phosphorylation of CREB (a BDNF
transcription activator) through PKA (303, 340). Activation of beta-adrenoreceptors can
directly phosphorylate TrkB, inducing signaling cascades that leads to the enhanced
transcription of BDNF and other genes (424).

Serotonin
Serotonin neurons located in the ventral tegmental area (VTA) and dorsal raphe
(DR) project to the nucleus accumbens (NAc) (97), amygdala (AMG), and frontal cortex,
regions that are part of the reward circuitry and development of alcohol addiction (425).
Increased alcohol intake and vulnerability to dependence has been positively correlated
with a decrease in serotonin (426, 427). Acute alcohol exposure increases serotonin
release, whereas chronic alcohol exposure decreases serotonin in humans (425-427). Rat
strains that demonstrate high levels of alcohol intake, such as the alcohol preferring P-rat,
deficits in serotonin signaling are seen (428). Additionally, to demonstrate the role of
serotonin in alcohol intake, serotonergic neurons in rats were lesioned with 5,6- and 5,7dihydroxytryptamine, resulting in increased alcohol drinking (425-427). Furthermore,
targeting serotonin 5-HT1A and 5-HT1B receptors with agonists reduced alcohol intake in
animals (425, 429). Blocking the serotonin transporter by genetic deletion or with selective
serotonin reuptake inhibitors (SSRIs), increased serotonin in the synapse and reduce
alcohol intake in rodent models of alcohol use (430). The effect of SSRI treatment to
reduce alcohol intake in humans is less well elucidated and the use of SSIR treatments
may be affective in a subset of individuals who develop alcoholism later in life (431).
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Exercise has been demonstrated to increase the availability of tryptophan, an
essential amino acid for the production of serotonin (5-HT) in the brain (432). The leucinepreferring (L-type) amino acid transporter traffics tryptophan into the brain, where it can
be converted to serotonin via the intermediate molecule 5-hydroxytryptophan (5-HTP).
Levels of tryptophan and serotonin were increased in the plasma and brain of rats that
exercised (433, 434). In humans, acute aerobic exercise increased serotonin in urine,
serum, and whole blood (435, 436). In rodents peripheral serotonin has been
demonstrated to cross into the brain from the blood via serotonin transporters located in
the blood brain barrier (437, 438).
Treatment with SSRIs reduce symptoms of depression and increases BDNF protein
levels (439-441). Both fluoxetine and citalopram, increased TrkB phosphorylation at the
PLC-γ1 site and not Shc binding sites (423, 442). Direct application of serotonin to
hippocampal neurons increased expression of BDNF in a dose dependent manner (443).
Serotonin signaling can upregulate BDNF expression through 5-HT2A/C, as antagonism
of the receptor using ketanserin attenuated exercise induced BDNF expression in the
hippocampus (412). This effect is further demonstrated by selective agonism of 5-HT1A
and 5-HT2A elevating Bdnf mRNA and protein in the HPC, DG, PFC, CeA, and NAc shell
of rats (444). The increase in BDNF may be mediated through enhanced CREB function,
as SSRI treatment increased phosphorylation of CREB, a well-known mediator of Bdnf
mRNA transcription (423).
The role of serotonin in the expression of BDNF may not be as clear as it seems.
Studies performed have elicited findings contrary to those previous stated. In one study 3
weeks of fluoxetine treatment did not increased hippocampal BDNF protein (445). Mice
genetically deficient of tryptophan hydroxylase, displayed elevated BDNF levels in the
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HPC (446). Furthermore, 5-HT1A antagonist WAY100635, did not attenuate BDNF
expression but enhanced it (412). However, this effect should be taken cautiously because
of the compound’s dopamine D4 receptor agonist properties (447, 448).

Endogenous Opioids
The opioidergic system, comprised of endogenous opioids (endorphins,
enkephalins and dynorphin) and their receptors mu (MOR), delta (DOR), and kappa (KOR)
are implicated in alcohol drinking behavior. For example, in rodents studies show βendorphin, an endogenous MOR agonist, was increased in the NAc and VTA after
exposure to alcohol (449, 450). After exposure to alcohol, alcohol preferring C57BL/6J
mice present higher β-endorphin levels than DBA/2 mice, an alcohol nonpreferring strain
(451). Furthermore, rodents with MOR and KOR knocked out or pharmacologically
inhibited with naltrexone (MOR antagonist) or nor-binaltorphimine (KOR antagonist)
reduced voluntary alcohol self-administration (78, 452-454)
Targeting opioid receptors is a current strategy for treating alcohol addiction.
Compared to control humans, alcoholics who underwent withdrawal presented increased
MOR expression in the ventral striatum, correlating with alcohol craving [443]. Positron
emission tomography (PET) imaging studies using carfentanil (synthetic opioid) showed
reduced MOR binding in the NAc after alcohol drinking (455, 456). In humans, naltrexone
treatment decreased the urge to drink alcohol and reduced the number of drinks
consumed (77, 457, 458). Activation of the MORs has been suggested to result in the
increase in dopamine release in the NAc (187) and blocking the receptor blunts release,
thereby reducing drug and alcohol intake (459, 460).
The positive rewarding effects and the feeling of euphoria, commonly referred to as
the “runners high” are a result of increased endogenous opioid release in the frontal cortex
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(459, 461). Adolescents that engaged in exercise used less prescription opioids and
heroin during their lifetime (462). Rats that performed resistance exercise displayed
reduced heroin self-administration (255, 256). Further, the exercise intensity (aerobic and
resistance) is positively correlated with beta-endorphin levels (459, 460). The induction of
endogenous opioids can elicit an analgesic response, which can be blocked by naloxone
administration (460). This provides an indication that the effect of exercise on drug may
reduce drug and alcohol intake by increasing endogenous opioids (186, 459).
Evidence exists indicating the ability of the opioid system to increase expression of
BDNF. Antagonism of the delta opioid receptor with BW373U86 increased BDNF in the
HPC, BLA and FC, with the ability of BW373U86 to increase BDNF being blocked by the
antagonist NTI (463). The delta-opioid receptor (DOR) agonist DPDPE dose dependently
increased Bdnf mRNA in the FC of rats (464). Administration of endogenous opioid
enkephalin (binds MOR and DOR), i.c.v. into the brain increased Bdnf mRNA in the
hippocampus (465). Where conversely, antagonism of MORs with naltrexone did not
affect the ability of BW373U86 to increase Bdnf mRNA (465). Kappa-opioid receptor
antagonism, with nor-BNI, increased BDNF protein expression in the HPC and AMG 24hr after administration i.c.v., while it did not significantly increase BDNF in the frontal cortex
BDNF did appear to be trending toward an upregulation (466).
The information above leads to realization that multiple, complex interaction and
potential mechanisms exist, by which exercise can induce the expression of BDNF in the
brain.

Study Objective
Information presented on the previous pages demonstrates a role of BDNF in the
brain to reduce alcohol intake and that exercise can increase BDNF and reduce alcohol
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intake. To date, it is unclear how exercise reduces alcohol intake, and there are no studies
that have looked at using exercise to elevate BDNF in the brain in the context of an alcohol
dependence (CIE) model. This dissertation aims to address the important research
question: can daily exercise increase BDNF expression in the brain and, through BDNFTrkB signaling, attenuate CIE-induced escalated alcohol drinking? Over the next three
chapters studies aim to show limited (2-hr/day) exercise (wheel running), prior to chronic
alcohol exposure (CIE vapor), can attenuate escalated alcohol drinking associated with
dependence through a BDNF-TrkB mediated mechanism.
Chapter 2: Effects of Limited Wheel Running on Bdnf mRNA Expression in the
Brain.
In Chapter 2 the main hypothesis that exercise under daily limited access conditions
(2-hr/day) will increase Bdnf mRNA and BDNF protein expression in target brain regions
(mPFC and DG) is tested. It is also hypothesized that daily limited access to alcohol will
not alter activity or exercise-induced elevated BDNF levels in brain.
Chapter 3: Effects of Limited Running on CIE-Dependent Drinking.
Chapter 3 examines the hypothesis that daily limited access to running wheels will
reduce CIE-induced escalated drinking in male mice, and this effect will be associated
with activity-related elevation of BDNF mRNA and protein expression in target brain
regions.
Chapter 4: Role of BDNF-TrkB Signaling in the Effects of Exercise (Wheel-Running)
on Alcohol Drinking in Dependent and Nondependent Mice.
In Chapter 4 studies test the hypothesis that systemic administration of the TrkB
antagonist ANA-12 will prevent/block the ability of running wheel activity to attenuate CIEinduced escalated drinking in male mice.
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Chapter 2 - Effects of Limited Wheel Running on
Bdnf mRNA Expression in the mPFC
Introduction
Alcohol use disorder (AUD) is a leading cause of preventable death and illness
(467). Chronic heavy alcohol (ethanol) use can lead to the development of alcohol
dependence, a chronic relapse disorder characterized by loss of control and compulsive
alcohol consumption, and negative symptoms associated with withdrawal (468, 469).
Currently there are only three FDA approved medications for the treatment of AUD and,
unfortunately, they are not fully efficacious in all treatment seeking individuals (30, 31).
Thus, there is a great need for discovery of new and more effective therapeutic
interventions.
A potential therapeutic target for the treatment of AUD is brain-derived neurotrophic
factor (BDNF). BDNF has been demonstrated to be involved in a number of alcoholrelated behaviors, including drinking and dependence (467, 468). For example, in
humans, a valine (Val) to methionine (Met) substitution at codon 66 confers a BDNF
polymorphism that results in the impairment of vesicular transport and secretion of BDNF
(272, 273). Several studies have demonstrated individuals with the Met variant have lower
serum BDNF levels (470, 471). However, other studies have provided evidence showing
people with the Met variant also display both no changes and elevated serum BDNF (469,
472, 473). In addition to being associated with anxiety, depression, and impaired memory,
the polymorphism is linked to early onset of alcohol abuse in humans (474, 475). Further
supporting the role of BDNF in alcohol addiction, human alcoholics display reduced blood
BDNF levels compared to healthy controls (321, 450, 476).
In rodent models, BDNF expression has been shown to regulate alcohol drinking.
For example, mutant mice with the val66met polymorphism display compulsive, excessive
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alcohol drinking (326). Additionally, transgenic mice generated with BDNF deficiencies or
those with global brain-inhibition of BDNF-TrkB signaling display increased alcohol intake
(299-301). Further supporting the role of BDNF in alcohol drinking behavior, when BDNFTrkB activity is increased in the striatum and mPFC, alcohol intake is decreased (154,
299, 302, 330, 332).
The P-rat is a selectively bred strain of rat that will consume high levels of alcohol.
These rats have reduced Bdnf mRNA and protein levels in the CeA and display
heightened anxiety (303). When P-rats consumed alcohol BDNF levels in the CeA
increased

and

anxiety

decreased

(304,

305).

Infusion

of

BDNF

antisense

oligodeoxynucleotides in to the CeA of rats increased alcohol drinking (306), further
confirming the role of the BDNF expression in alcohol drinking, specifically in the CeA.
The striatum is another region of the brain that can regulate alcohol drinking
behavior through BDNF-TrkB signaling. Unlike the CeA, BDNF in the striatum tends to
increase alcohol consumption. For example, chronic alcohol vapor exposure and voluntary
alcohol drinking increased BDNF expression in the ventral striatum (VS) of rats (307, 309).
Binge drinking was blocked when BDNF’s primary receptor, TrkB, was inhibited with the
antagonist ANA-12 (317). The dorsal lateral striatum (DLS) is a brain region involved with
the regulation of habit behavior, whereby subjects will continue to perform a behavior even
when value is no longer associated with the action. Following alcohol administration, the
DLS shows elevated BDNF expression (299, 316, 319, 320).
The medial prefrontal cortex (mPFC) regulates top-down control of executive
function (110-112). It is also responsive to alcohol cues (125, 126) and is involved in
alcohol seeking behaviors (26-28, 108, 109). Expression of BDNF in the medial prefrontal
cortex (mPFC) has been directly linked to alcohol drinking behavior in rodent models of
dependence. Repeated cycles of alcohol vapor exposure have been demonstrated to
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increase alcohol intake in rats and mice (166, 170, 172, 477-479) and cause reduced Bdnf
mRNA and protein expression in the mPFC of rats and mice [152, 311, 312, 455].
MicroRNA-206 (miR-206) is a negative repressor of Bdnf mRNA, that is over expressed
as a result of alcohol dependence (330, 332). Over-expression of miR-206 in the mPFC
enhanced alcohol intake in nondependent rats (307). The importance of BDNF in the
mPFC in regard to alcohol dependence is illustrated in studies where alcohol dependent
mice had BDNF protein infused directly into the mPFC, blocking escalated alcohol drinking
(169). Additionally, over-expression of BDNF in the mPFC prevented the development of
alcohol dependent-like drinking (169). These results indicate a significant role of BDNF in
the mPFC in the regulation and treatment of alcohol dependence drinking.
The BDNF gene is a complex gene comprised of 9 exons that act as unique
promoter sequences for the regulation of BDNF transcription (244, 260, 284) and aid in
trafficking of BDNF throughout neurons (263, 264). The greatest expression of BDNF is in
the hippocampus and cortex of the brain, with expression occurring in all cell types (243,
244). All exon variants are individually spliced to exon IX which encodes the functional
BDNF protein [245]. Of the variants, exons I and IV are 2 of the most abundant versions
in the brain and are expressed in an activity-dependent manner (244, 265, 284). Overexpressing Bdnf exons I and IV in neurons increased TrkB phosphorylation, a sign of
increased BDNF protein expression and TrkB signaling (278). Mice rendered alcohol
dependent by vapor exposure showed reductions of Bdnf exon I, IV, and IX mRNA in the
mPFC and HPC of mice (173, 460). As described above, manipulating the expression of
BDNF in the mPFC can impact the consumption of alcohol. However, there is limited
clinical ability to elevate BDNF in the mPFC through traditional modern medical
approaches. Hence, an alternative, non-invasive approach to increasing BDNF
expression in the brain is of high treatment value.
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Exercise is a non-pharmacological approach being investigated for the treatment of
AUD. Exercise is naturally rewarding to humans and animals and it is voluntarily performed
by rodents (137, 213, 223, 224). Both aerobic and resistance exercise will increase BDNF
levels in the DG of rodents (217, 218, 258, 259, 299) and in plasma and serum of humans
(346-348, 350-354). Exercise has been shown to reduce alcohol intake in adolescent and
adult humans as well as improve abstinence (24, 25, 231, 238-245). Additionally, exercise
has been shown to reduce alcohol drinking in rodent models (217, 224, 237). While the
mechanism by which exercise influences motivation to drink alcohol in unclear at present,
several possibilities have been advanced. For example, exercise may be useful as a
treatment for AUD due to its general health benefits, including improving physical and
mental health, providing an alternative to alcohol use, and reduces stress (136, 138, 208,
213, 219, 221, 223). Thus, exercise may prevent or reverse deficits in BDNF caused by
chronic alcohol exposure, thereby reducing motivation to drink.
In exploring the effects of exercise on alcohol intake, current published work is limited
and has mainly focused on voluntary levels of alcohol intake over 24 hours. For example,
when mice were given 24-hr concurrent access to a running wheel and 10% alcohol for 23 weeks, a reduction in alcohol intake was seen in female but not male C57BL/6 mice (223,
232). Neither sex of mice displayed altered binge-like alcohol intake in the “Drinking in the
Dark” paradigm after 11 days of continuous access to wheel-running (90). In another study,
alternating weeks of 24-hr wheel running either in the presence or absence of 10% alcohol
did not alter intake in male C57BL/6J mice (226). A study conducted using Lewis rats with
unlimited access to a running wheel during a 1- or 2-week alcohol withdrawal period
increased subsequent alcohol intake (225). The different methodologies, species, sex, and
the varying number of days wheel access was provided limit our ability to fully interpret the
effects of running on alcohol intake.
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A common methodological feature of published studies described above is that
rodents had continuous and concurrent access to both wheel-running and alcohol
drinking. Drinking and running are competing behaviors that cannot be performed
simultaneously in rodents and can obscure the possible effect one behavior may have on
the other. Additionally, humans typically schedule periods of time in which they exercise.
Therefore, providing unlimited wheel access in rodent models does not optimally translate
to human behavior. To our knowledge, the effects of daily limited access to exercise
(wheel-running) on alcohol consumption has not been explored. Further, to examine the
potential for BDNF to play a role in the effects of exercise on alcohol drinking, it is critical
to determine whether scheduled access to wheel-running alters BDNF expression in brain.
Accordingly, the aim of this study was to determine whether daily limited access to
an activity wheel in the home cage (2-hr/day) for six weeks alters alcohol consumption
and whether this scheduled exercise regimen results in elevated Bdnf mRNA expression
in the mPFC. The DG was also analyzed as a positive control, as it is a region well known
to demonstrate exercise induced increases in BDNF (217, 218, 299). In Experiment 1 mice
were provided 2-hr/day home-cage running wheel access to determine if limited wheel
access would be sufficient to increase Bdnf mRNA and protein levels in the mPFC and
DG. Experiment 2 introduced 2-hr alcohol drinking 1-hr prior to wheel access. This
experiment examines the effects of alcohol drinking and exercise have on each other and
Bdnf mRNA expression. Wheel running was provided after alcohol access to avoid any
influence of exercise on general thirst and/or the need for more calories.
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Methods
Subjects
Adult male C57BL/6J mice purchased from Jackson Laboratories (Bar Harbor, ME)
were individually housed under a 12-hr light/dark cycle (lights on at 8:00 AM). Mice were
maintained in a temperature and humidity controlled AAALAC-accredited facility at the
Medical University of South Carolina, with food (Teklad rodent diet) and water available
ad libitum. Mice were weighed weekly during the course of the experiments. All
procedures were approved by the Institutional Animal Care and Use Committee and
conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals.

Wheel-Running
Mice were given home-cage access to an activity wheel (Bioserve cat #S3174 and
S3175) 2-hr/day beginning 6 hours in the dark cycle. The distance mice ran was tracked
and calculated using bike computers (Enkeeo Model BKV-1527) attached to the running
wheels. The No-Wheel groups were left undisturbed in their home cages.

Brain Tissue Collection
Mice were sacrificed by decapitation and brains rapidly removed. The medial
prefrontal cortex (mPFC) and dentate gyrus region of the hippocampus (HPC) were
dissected on ice using 1-mm microdissection punches, with the mouse brain atlas serving
as a guide (480). Tissue samples were placed into RNA Later (Thermo Fisher; cat no.
AM7021). Total RNA was extracted from the brain tissue samples ReliaPrep RNA
extraction kit (Promega; cat no. Z6012) according to the manufacturer’s instructions. Total
RNA was quantified on a Denovix DS-11FX spectrophotometer. Tissue collected for
BDNF ELISA assay was frozen on dry ice and stored in at -80°C until use, described
below.
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qRT-PCR
Quantitative real time-polymerase chain reaction (qRT-PCR) assays were
performed using similar procedures to those previously published by our group (178). For
Bdnf exon I, IV, and IX mRNA measurements, cDNA was created using QuantiTect
Reverse Transcription Kit (Qiagen; cat no 205314) according to manufacturer’s
instructions. Custom designed TaqMan qRT-PCR primers were used to specifically target
and amplify BDNF I mRNA, were designed using Integrated DNA Technologies (IDT)
primer designer online software and manufactured by Life Technologies (BDNF I,
Forward: GATGCCAGTTGCTTTGTCTTC; Reverse: CCACCACTTGGTGTGACTTAT;
Probe:

TCGCCAAGGTGGATGAGAGTTGAA;

BDNF

IV,

Forward:

GCCTAGATCAAATGGAGCTTCT; Reverse: GCCGATATGTACTCCTGTTCTG; Probe:
ACCTCCGCCATGCAATTTCCACTA;

BDNF

IX,

Forward:

GTGACAGTATTAGCGAGTGGG; Reverse: GGGATTACACTTGGTCTCGTAG; Probe:
CAGTTGGCCTTTGGATACCGGGA)s. Cyclophilin (Ppia) (Life Technologies) was used
as the reference gene, for data normalization. For the reactions, 10 µl of sample cDNA
and TaqMan Universal Master Mix II, with UNG (Applied Biosystems; cat no 4440042),
were loaded in triplicate into a 384-well optical PCR plate and analyzed on a BioRad
CFX384 Real Time PCR system. Cycling parameters: 50° C for 2 min, 95° C for 10 min,
followed by 40 amplification cycles with melting at 95° C for 15 sec, and
annealing/extending at 60° C for 60 sec. Fluorescence readings are obtained after each
cycle. The 2^-DDCT method (481) was used to calculated fold change in expression of
the target gene (BDNF I) relative to the reference gene (Ppia) using the CTL group as the
reference condition.
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ELISA
Brain-derived neurotrophic factor (BDNF) was assayed using BDNF Duo ELISA (R
& D Systems) as per manufacturer’s instructions. Briefly, brain tissue was lysed in 1%
BSA in PBS pH 7.4 via sonication. Standards (0-1500 pg/mL) and samples were added in
duplicate to a 96-well plate, coated with BDNF-capture antibody and blocked with 1%
bovine serum albumin (BSA). Plates were incubated at room temperature for 2-hr and
washed with Wash buffer (0.1% Tween in PBS). Detection antibody was added to a 96well microplate and incubated at room temperature for 2-hr and then washed with Wash
buffer. Strepavidin-HRP was added to each well and incubated 20-min. 50-µL Stop
solution (Thermo) was added to well and plate was washed with Wash buffer.
Statistical analysis
All statistical analyses were performed using SPSS Statistics version 25. Statistical
significance for all analyses was set at p<0.05. In Experiment 1, average running distance
(km) over the last 7 days was analyzed by ANOVA, with Group as the main factor. Weekly
body weight (grams) was analyzed by Repeated Measures ANOVA, with Group as the
between-subjects factor and Week as a within-subjects factor. Pairwise comparisons with
Bonferonni corrections were performed when appropriate. BDNF qRT-PCR (fold change)
and ELISA (percent of Control) data were analyzed by ANOVA with Group as the factor
with mRNA or protein levels as the dependent variable. When appropriate pairwise
comparisons with Bonferonni corrections were performed. With average weekly alcohol
intake (g/kg) as the independent variable, Repeated Measures ANOVA was performed
with running access as the dependent variable. Pairwise comparisons with Bonferonni
corrections were performed when appropriate.
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Experimental Design and Procedure
Experiment 1: Effects of 2-hr/day Wheel Access on Running, Bdnf mRNA and
Protein Expression in the mPFC and DG of C57BL/6J Mice.
This study included 5 groups (N= 8-14/group). Four groups of mice were given
access to wheel-running for 4 weeks. Separate groups of mice were sacrificed 24-hr, 1wk, or 2-wk after the final day of running. An additional group was given 2-days access to
wheel-running after the 2-wk time point and sacrificed 24-hr later. The fifth group of mice
did not receive access to activity wheels (NWH). These mice (NWH group) were sacrificed
at each of these time points. Brains were extracted and dissected on ice for BDNF protein
and mRNA analysis.
Experiment 2: Effects of Alcohol Drinking on Limited Access Wheel-Running and
Bdnf mRNA Expression in the mPFC and DG of C57BL/6J Mice.
This study involved a 2 (Group: Wheel, No-Wheel) x 2 (Alcohol: EtOH, water)
design, yielding 4 groups (N=9-12/group). Mice in the EtOH groups received 1 bottle of
alcohol (15% v/v ethanol) and 1 bottle of water in their home cage for 2 hours, starting 3hr into the dark cycle. The remaining mice received 2 bottles of water. One hour following
removal of bottles, mice in the running groups (WH-EtOH, WH-water) were given home
cage access to a running wheel for 2 hours. Wheel access occurred 7 days a week and
drinking sessions occurred Monday to Friday (5 days). The experiment lasted 6 weeks
and mice were sacrificed 24-hr after the final day, brains extracted and dissected on ice.
Total RNA was isolated from select brain regions (mPFC, DG) for mRNA analysis by qRTPCR.
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Figure 2.1 - Schematic representation of Experiment 1 and 2.
(A) Experiment 1: 5 groups (N= 8-14/group). 4 groups of mice were given access to wheelrunning (2-hr/day) for 4 consecutive weeks. Groups were sacrificed 24-hr, 1-wk, or 2-wk
after the final day of wheel-running with one group receiving 2-days access to a running
wheel after the 2-wk time point and sacrificed 24-hr later. Control mice (NWH group) were
sacrificed at each of these time points. (B) Experiment 2: 2 (Exercise: Wheel, No-Wheel)
x 2 (Alcohol Access: EtOH, water), 4 groups (N= 9-12/group). Mice received 1 bottle of
alcohol (15% v/v ethanol) and 1 bottle of water (EtOH groups) or 2 bottles of water (water
groups) for 2-hr. Mice in wheel-running groups (WH-EtOH, WH-water) had 2-hr home
cage wheel access 1-hr after the drinking session. Mice were sacrificed at 24-hr after the
final day of the study.
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Results
Experiment 1: Limited Exercise (2-hr/day) Increases BDNF in the mPFC and DG
During the 4 weeks of daily limited access (2-hr/day) to activity wheels in the home
cage all mice reached stable levels of wheel-running (Figure 2.2). One-way ANOVA of
average distance ran during the last 7 days revealed no differences between the groups
[F(3,47)= 0.11, p= 0.953].
Mice with daily limited access to wheel-running (WH groups) gained less weight over
the 4-week test period in comparison to NWH mice (Figure 2.3). This was confirmed by
ANOVA, which revealed significant main effects of Group [F(4, 55)= 4.59, p< 0.003], Week
[F(4,220)= 56.94, p< 0.005], and the Group x Week interaction [F(16,220)= 4.10, p<
0.005]. While all mice gained weight over time, at Week 4 all WH groups weighed
significantly less than NWH mice (p<0.05). Further, reduced body weight persisted for 2
weeks following cessation of wheel-running access in the 2-wk and 2-Wk+2-day groups
[F(2,29)= 6.03, p< 0.007] (Figure 2.3).
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Figure 2.2 – Experiment 1: Average Daily Wheel Running.

No difference in Group average daily wheel running (km) over the last 7 days of
running. Values are mean ± s.e.m. (N= 8-14/group)

60

Body Weight (g)

35

NWH
WH-24hr
WH-2wk+2days

WH-1wk
WH-2wk

*

30

25

20

Initial

1

2

3

4

5

6

Week
Figure 2.3 – Experiment 1: Weekly Body Weights
Exercise (WH) resulted in lower body weights compared to sedentary group (NWH) at the
end of 4 weeks, main effect of Group (p<0.003). Values are mean ± s.e.m. (N=8-14/group).
Significantly differs from NWH (*p<0.05).
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Analyses of Bdnf mRNA exons I, IV, and IX and BDNF protein were performed on
tissue from the mPFC and DG, with the latter brain region selected because it is a region
where exercise is well known to increase BDNF expression (136, 137). In the mPFC,
exercise significantly increased Bdnf exon I mRNA (Figure 2.4 A), as indicated by a main
effect of Group [F(5,52)= 10.26, p< 0.0005]. Post -hoc comparisons indicated that 24-hr
after 4 weeks of daily running (WH-24-hr), Bdnf exon I mRNA was significantly elevated
relative to the NWH condition (p< 0.05). This increase normalized to control (NWH) levels
1-week and 2-weeks after activity wheels were removed. However, two days of 2-hr
running following 2 weeks of inactivity (2-wk+2-day) resulted in significantly increased
Bdnf exon I mRNA expression compared to the NWH group (p< 0.05). Analyses of
exercise effects on Bdnf exon IV mRNA expression in mPFC revealed a similar profile of
results (Group [F(4,53)= 4.03, p< 0.007]). Post-hoc comparisons indicated that only the
24-hr and 2-wk+2-day groups displayed significantly increased Bdnf exon IV mRNA
compared to NWH, 1-wk, and 2-wk groups (ps< 0.05). Analysis of Bdnf exon IX mRNA
indicated a main effect of Group [F(4,54)= 3.38, p< 0.02]. Further analysis demonstrated
a significant increase in expression for 24-hr and 2-wk+2-day groups compared to the 1wk and 2-wk groups (ps< 0.05) and a trend for increased expression compared to NWH
(ps< 0.1).
In the DG, exercise significantly increased Bdnf exon I mRNA expression relative to
the NWH condition, as indicated by a significant main effect of Group [F(4,48)= 8.48, p<
0.0005]. Post-hoc comparisons indicated that this effect was evident at 24-hr and 1-week
following the 4-week scheduled wheel-running access period (ps< 0.05). While Bdnf exon
I mRNA expression in DG returned to control (NWH) levels after 2-weeks, only two days
of 2-hr wheel-running was required to significantly elevate Bdnf exon I levels (p< 0.0005)
(Figure 2.4B). Analysis of Bdnf exon IV mRNA expression in DG indicated a significant
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main effect of Group [F(4, 55)= 5.16, p< 0.001]. Interestingly, unlike exon I, 24-hr and 1wk WH groups did not show changes in mRNA expression compared to the NWH
condition, but 2 weeks after the 4-week wheel-running access period there was a
significant reduction in exon IV expression (p< 0.05). When wheel-running access
resumed for two daily 2-hr sessions (2-wk+2-day group), there was only a trend toward
an increased in mRNA expression compared to the NWH condition (p= 0.096) (Figure
2.4B). Analysis of Bdnf exon IX expression in DG revealed a main effect of Group
[F(4,54)= 3.18, p< 0.03]. Significant increases in exon IX mRNA expression were evident
in the 24-hr and 1-wk WH groups compared to the NWH group (ps< 0.05). This effect
normalized after 2 weeks and an additional 2 days of wheel-running did not significantly
elevate Bdnf exon IX expression in DG (Figure 2.4B).
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Figure 2.4 – Experiment 1: Bdnf mRNA Expression in DG and mPFC
(A) DG (B) mPFC relative to sedentary (NWH) control group. (A) Exon I: main effect of
Group (p<0.0005); exon IV: main effect of Group (p<0.001); exon IX: main effect of Group
(p<0.03). (B) Exon I: main effect of Group (p<0.0005); exon IV: main effect of Group
(p<0.007); exon IX: main effect of Group (p<0.1). Values are mean ± s.e.m. (N=814/group). Differs from NWH (*p<0.05; #p<0.1).
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In tissue collected from the same animals, BDNF protein was assayed by ELISA
(Figure 2.5 A & B). Analysis of BDNF protein levels in the mPFC (Figure 2.5A) indicated
a significant main effect of Group [F(4,41)= 6.61, p< 0.0005]. Protein was significantly
increased in the 24-hr and 1-wk WH groups relative to NWH condition (ps< 0.05) and then
returned to NWH levels after two weeks of no running (2-wk WH group). Similar to mRNA
expression, 2 days of 2-hr running (2-wk+2-day group) was sufficient to significantly
elevate protein levels in mPFC compared to the NWH group (p< 0.05). ANOVA of BDNF
protein isolated from the DG (Figure 2.5B) revealed a main effect of Group [F(4,49)=3.47,
p<0.015], with all wheel-running groups displaying significantly elevated levels compared
to the NWH group (ps<0.05).
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Figure 2.5 – Experiment 1: BDNF Protein Expression
BDNF protein expression measured by ELISA (A) DG, main effect of Group (p<0.015).
(B) mPFC, main effect of Group (p<0.0005). Values are mean (pg Bdnf/mg total protein)
± s.e.m. (N=6-10/group). Differs from NWH (*p<0.05).

66

Experiment 2: Voluntary Alcohol Drinking Does Not Affect Exercise Induced
Bdnf mRNA expression in the mPFC or DG
This experiment examined whether alcohol drinking and exercise (wheel-running)
interact to influence Bdnf mRNA expression in the mPFC and DG. As in Experiment 1,
wheel-running (2-hr/day) was relatively consistent and this was true regardless of whether
mice were given access to drink alcohol (15% ethanol) (Figure 2.6). Analysis of daily
activity expressed as distance (km) during the last 7 days of the 6-week experiment
supported this observation in that the main factor Alcohol Access was not significant
[F(1,19)= 0.15, p= 0.7].
While all groups gained weight over the course of the 6-week study, ANOVA
indicated a significant main effect of Exercise [F(1,40)= 5.20, p<0.03] and the Exercise x
Week interaction [F(5,200)= 6.88, p< 0.005]. Post-hoc comparisons indicated that wheelrunning mice weighed less than NWH mice at Weeks 2-6 (ps< 0.05). This effect was
evident in mice with or without access to alcohol (Exercise x Alcohol Access x Week
interaction: [F(5,200)= 1.28, p=0.27 ] (Figure 2.7).
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Figure 2.6 - Experiment 2: Weekly body weights.
Alcohol (15% v/v ethanol) drinking did not affect body weight. Exercise (WH) running
caused lower body weights compared to sedentary (NWH) mice, main effect of Group
(p<0.03). Values are mean ± s.e.m. (N=9-12/group). Significantly differs (*p<0.05).
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Figure 2.7 - Experiment 2: Average Daily Wheel Running.
Average daily running (km) over the last 14 days of Baseline. No effect of alcohol to alter
running. Main effect of Group over the last 7 days of running (p=0.7). Values are mean ±
s.e.m. (N=9-12/group).
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The effects of exercise on alcohol consumption (2-hr wheel-running occurring 22-hr
prior to the beginning of the alcohol access periods) are presented in Figure 2.8A and
2.8B. While mice without access to activity wheels (NWH group) maintained relatively
stable levels of alcohol intake (g/kg) over the 6-week experiment, WH mice consumed
more alcohol beginning the third week of the study (Figure 2.8A). This was supported by
ANOVA, which indicated a significant main effect of Exercise [F(1,24)= 4.20, p<0.005] and
an Exercise x Week interaction [F(5,120)= 3.50, p<0.005]. Post-hoc comparisons
indicated that alcohol intake was significantly greater in WH mice compared to the NWH
group during Weeks 4-6 (ps< 0.05). Additionally, given that mice with access to activity
wheels evidenced reduced weight over the course of the study, alcohol intake expressed
as volume (ml) was analyzed as well. Similar to results with data expressed as g/kg,
increased alcohol consumption was observed in wheel-running mice (Figure 2.8B).
Although ANOVA indicated a trend for a significant main effect of Exercise [F(1,24)= 2.92,
p<0.1], the Exercise x Week interaction was significant [F(5,120)= 2.8, p<0.05]. Post-hoc
tests revealed that wheel-running significantly increased volume of alcohol consumed
during Week 6 (p< 0.002) and a trend for increased intake during Week 4 (p< 0.08).
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Figure 2.8 - Experiment 2: Baseline Alcohol Intake.
(A) g/kg (B) mL. (A) Exercise x Week interaction (p<0.005), main effect of Exercise (WH)
(p<0.005) (B) Exercise x Week interaction (p<0.005), main effect of Exercise (p<0.1).
Values are mean ± s.e.m. (N=9-12/group). Differs from NWH-EtOH group (*p<0.05;
#p<0.1).
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Examination of brain tissue at the end of the study indicated that exercise
significantly increased Bdnf mRNA expression in the mPFC and DG, and this was true
whether mice had access to alcohol during the study. Analysis by ANOVA indicated a
significant main effect of Exercise, with increased expression of Bdnf mRNA exon I
[F(1,35)= 16.09 p< 0.0005], exon IV [F(1,34)= 13.27, p< 0.001], and exon IX [F(1,36)=
9.81, p< 0.004] in the mPFC (Figure 2.9A). In the DG (Figure 2.9B) Bdnf mRNA displayed
a similar profile of results, with a main effect of Exercise for of exon I [F(1,34)= 27.25, p<
0.0005], exon IV [F(1,33)= 6.19, p< 0.02], and exon IX [F(1,39)= 12.57, p< 0.001].
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Figure 2.9 – Experiment 2: Bdnf mRNA Expression in DG and mPFC
(A) DG (B) mPFC relative to Control (NWH). (A) Main effect of Exercise (WH) exon I
(p<0.0005), exon IV (p<0.02), exon IX (p<0.001). (B) Main effect of Exercise exon I
(p<0.0005), exon IV (p<0.001), exon IX (p<0.004). Values are mean ± s.e.m. (N=710/group). Differs from NWH groups (*p<0.05).

73

Discussion
The aim of these studies was to determine if daily limited access (2 hr/day) to
exercise (wheel-running) over multiple weeks increased Bdnf mRNA and protein
expression in the mPFC, a region implicated in contributing to escalated alcohol drinking
associated with dependence (174). Results indicated that this regimen of exercise
significantly elevated Bdnf mRNA and BDNF protein levels in the mPFC as well as the DG
subregion of the hippocampus. Additionally, results demonstrate the ability of exercise to
rapidly elevate Bdnf mRNA and BDNF protein in the mPFC and DG of mice with a history
of wheel running, replicating similar findings previously reported in the DG of rats (137).
Continuous (unlimited) daily access to wheel-running is well-known to increase
BDNF (mRNA and protein) expression in the DG (136, 137, 213). Complementing these
findings, our results show that a daily limited schedule of exercise (2-hr/day wheelrunning) over several weeks significantly increased BDNF expression in the DG and in the
mPFC. Similar to mice with unlimited access to an activity wheel (136-139, 235, 236),
mice provided wheel access in the home-cage 2-hr/day maintained consistent levels of
running over the course of several weeks. Further, daily alcohol intake did not affect wheelrunning behavior or influence the ability of exercise to elevate BDNF expression in the
target brain regions. Interestingly, wheel-running produced a modest increase in alcohol
consumption even though the scheduled 2-hr wheel access occurred 21-hr prior to alcohol
access.
Chronic alcohol exposure has been shown to reduce Bdnf mRNA expression in
multiple brain regions, including the cortex (325, 328, 482, 483) and hippocampus (484,
485). Using a well-established mouse model of alcohol dependence that involves repeated
cycles of CIE exposure, our laboratory has demonstrated similar effects (174, 178, 486).
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Further, increasing BDNF activity in the mPFC via direct microinjection of the neurotrophic
factor or viral-mediated over-exppression of BDNF significntly reduced escalated alcohol
drinking associated with dependence (174). Collectively, these data support the notion
that BDNF activity in the mPFC contributes to the regulation of alcohol consumption,
making the BDNF-TrkB system a potential target in the treatment of alcohol addiction.
Unfortunately, no pharmacological treatments are availble that specifically target BDNFTrkB system for use in the treatment of alcohol addiction.
Exercise has been shown to reduce the development of dependence (231, 243),
improve abstinence (241-244), and reduce alcohol intake (241, 474, 475). Both resistance
and aerobic exercise increase BDNF levels in humans and rodents (136, 221, 255, 256,
339, 340). This suggests that exercise may be a viable non-pharmacological strategy to
increase BDNF levels and thereby exert therapeutic effects in the treatment of alcohol
addiction.
Few studies have examined the effects of exercise on alcohol drinking behavior. In
those published studies, mice had concurrent, unlimited access to alcohol and an activity
wheel in the home-cage (138, 139, 235, 236). This approach may confound drinking
results because these are competing behaviors that cannot be performed simultaneously.
Additionally, unlimited access to alcohol in the home-cage may obscure subtleties in
drinking behavior (e.g., temporal patterns of alcohol intake in relation to exercise). As well,
humans do not typically exercise throughout the course of their day, but rather perform
exercise during designated time periods. Therefore, the present studies were designed to
temporally separate access to alcohol and exercise.
In the present studies, activity wheels were provided in the home-cage after the
alcohol drinking session was terminated to avoid an influence of exercise on a need for
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more calories or from an overall increase in thirst. Interestingly, exercise had a modest
effect of increasing alcohol consumption, an effect that emerged around the 4th week of
the study (Experiment 2). Although body weights of wheel-running mice were lower than
sedentary mice, this effect was observed at the end of the study (Week 6) for volume of
alcohol consumed, even though the drinking sessions occurred 21-hr after the daily
scheduled exercise period. An explanation for this effect is not clear at present. Of note,
in similar studies, exercise (wheel-running) did not alter alcohol consumption when access
was restricted to 1-hr rather than 2-hr each day.
In contrast to our results, studies have shown access to a running wheel produced
a reduction in alcohol intake, however, this effect was only observed in female mice given
concurrent, unlimited activity wheel and alcohol (10% ethanol) access (136, 138, 139).
Other studies have shown increased alcohol intake, but only when exercise was restricted
to periods of alcohol deprivation in rats (236) or after 12 days of wheel-running in
C57/BL6cr mice (487). Taken together, published work indicates that the relationship
between exercise and alcohol consumption is complicated and outcomes may differ due
to differences in methodology (e.g., limited vs. unlimited and concurrent vs. nonconcurrent
access to exercise and alcohol drinking; species; sex).
A number of limitations should be noted in the present experiments. While unlimited
daily wheel-running has been shown to not affect food intake in mice (136), we did not
measure food consumption in our limited access model. Further, although exercise is
known to alter neurotransmission of endogenous opioid peptides and catecholamines
(399, 400, 414-416). Such changes in neurotransmitters can influence alcohol intake (192,
488), these effects were not examined in the present experiments. Also, since only the
daily scheduled exercise periods were 2-hr in duration, it is not clear whether longer
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access to activity wheels (e.g., 4- or 6-hr) would produce more robust effects on BDNF
expression and alcohol consumption. Finally, as only males were evaluated in these
experiments, it is unclear whether study outcomes may differ between male and female
mice.
In summary, results from the present studies indicate that daily 2-hr access to wheelrunning over several weeks significantly increased Bdnf mRNA and BDNF protein
expression in both the mPFC and DG brain regions. Wheel-running behavior was
relatively stable throughout the experiments, regardless of whether mice had access to
alcohol 1-hr following the exercise period. Additionally, this scheduled exercise regimen
produced a modest increase in alcohol consumption that emerged after 3-4 weeks. This
effect was observed even though alcohol was presented to the mice (2-hr/day) starting
21-hr after the previous exercise session. These data provide the foundation for follow-up
studies aimed at examining the effects of exercise on escalated drinking associated with
dependence and whether such effects are related to exercise-induced elevation of BDNF
expression in brain.
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Chapter 3 - Effects of Limited Running on CIEDependent Drinking
Introduction
An overarching conceptualization of alcohol addiction is commonly considered to
entail a cycle of 3 main stages: 1) preoccupation/anticipation (craving) where an individual
has a compulsory need to seek out and consume alcohol, 2) loss of control over alcohol
use (binge drinking and intoxication), 3) withdrawal and negative affective state (eg.
Dysphoria) (2). Repeated cycles of heavy alcohol use to intoxication followed by
withdrawal and abstinence leads to the development of alcohol dependence (154, 167,
168). Alcohol dependence leads to dysregulation in cortical and sub-cortical pathways
which regulate behavioral responses to reward and that govern behaviors related to
compulsive, repetitive alcohol use (38, 39).
Top-down control of executive function involved in addiction-related behavior is
mediated by the medial prefrontal cortex (mPFC) (104, 105). Altered brain function is
mediated by disruptions in neurotransmitter and neuropeptide production, release, and
signaling, leading to enhanced alcohol seeking and consumption (6, 51, 71, 192, 489).
Additionally, neurotrophic factors have been shown to play a role in contributing to the
addiction process. Specifically, brain-derived neurotrophic factor (BDNF) has been
implicated by multiple studies to be a key player in addiction-related behavior (174, 313,
325, 328, 490).
In alcohol dependent humans (alcoholics), BDNF in blood plasma and serum is
shown to be reduced compared to healthy control individuals (315, 316). Rodent models
of alcohol dependence reveal Bdnf mRNA and BDNF protein is decreased in the mPFC
of the brain (178, 326, 486). Other regions of the brain including the striatum and amygdala
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have shown changes in BDNF expression as a result of alcohol use (323, 468). Strains of
rats bred to consume greater amounts of alcohol, such as the P-rat, have been found to
have reduced BDNF (mRNA and protein) in the brain (321, 476). The role of BDNF in
alcohol drinking behavior is further demonstrated in transgenic mice transgenic mice that
express lower levels of BDNF, whereby these mice consume more alcohol than wild-type
controls (317-319). When BDNF is directly infused in the mPFC of alcohol dependent mice
it prevents the escalation in alcohol intake demonstrated during dependence (174). This
latter finding provides more direct evidence of the role of BDNF in the regulation of alcohol
consumption.
Chronic intermittent ethanol (CIE) exposure, is a well-established paradigm for
inducing alcohol dependence in rodents. When C57BL/6J mice are exposed to repeated
cycles of alcohol vapor followed by withdrawal they develop dependence-like behavior,
demonstrated by increased alcohol intake in 2-hr test drinking sessions (157, 172) and in
operant self-administration procedures (177, 491). The increase in alcohol intake induced
by CIE exposure increases blood alcohol concentration and is specific to alcohol-related
reward as sucrose intake is not altered in CIE exposed mice (154). Chronic alcohol
exposure results in neurochemical and molecular changes, including changes in BDNF
expression in the mPFC (174, 178, 326). Viral-mediated over-expression of BDNF in the
mPFC of mice prior to repeated cycles of CIE exposure blocked the development of
dependence-related escalated alcohol drinking (174).
It has been well established that aerobic exercise increases Bdnf mRNA and
BDNF protein expression in the hippocampus (dentate gyrus; DG) of rodents (136, 137,
342). In Chapter 2 we demonstrated limited daily voluntary wheel running was able to
increase Bdnf mRNA in the mPFC in addition to the DG of C57BL/6J mice. Exercise, both
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aerobic and resistance, has been shown to reduce drug and alcohol intake in rodents and
humans (221, 255, 256, 338). To the best of our knowledge, the effects of exercise on
drinking in the context of alcohol dependence has not been explored. Additionally, it is
unknown whether exercise increases BDNF in human alcoholics.
Based on the ability of exercise to increase BDNF (mRNA and protein) in the
mPFC (demonstrated in Chapter 2), and the fact that elevating BDNF in the mPFC via
microinjection or viral-mediated overexpression in mPFC blocks and/or prevents CIEinduced escalated alcohol intake (174), we tested the hypothesis that voluntary wheel
running would attenuate CIE-induced escalated alcohol intake. It was also hypothesized
that exercise would prevent CIE-induced reductions in Bdnf mRNA in the mPFC.

Methods
Subjects
Adult male C57BL/B6J mice were purchased from Jackson Laboratories (Bar
Harbor, ME). Mice were individually housed under a 12-hr light/dark cycle (lights on at
8:00 AM) in a temperature and humidity controlled AAALAC-accredited facility at the
Medical University of South Carolina, with food (Teklad rodent diet) and water ad libitum.
All procedures were approved by the Institutional Animal Care and Use Committee and
conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals.

Study Design and General Procedure
The study was conducted as a 2 [Exercise: wheel, no-wheel] x 2 [Group: CIE, Air]
factorial. All mice received 2-bottle choice drinking in the home-cage (15% v/v ethanol vs.
tap water) for 2-hr, starting 3-hr into the dark cycle. Alcohol access occurred Monday
through Friday (5 days) (Figure 3.1). Alcohol intake in g/kg was calculated by weighing
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bottles before and after the drinking session. Body weights were collected weekly to
calculate alcohol intake.
During the 6-week Baseline period, mice in the wheel running group (WH) were
given home-cage access to a running wheel for 2-hr, 7-days/week, 1-hr after the 2-hr
drinking sessions. Mice in the no-wheel condition (NWH) were left undisturbed in the
home-cage. At the end of the Baseline phase of the study, WH and NWH mice were further
divided into groups for chronic intermittent alcohol vapor (CIE) or air (AIR) exposure,
generating four groups (NWH-Air, NWH-CIE, WH-Air, WH-CIE). Mice were exposed to
repeated cycles of CIE or AIR, 16-hr/day for 4 days, followed by a 72-hr alcohol
withdrawal/abstinence period. Exercise (wheel access) was suspended during CIE/AIR
exposure and resumed 24-hr after mice were removed from inhalation chambers.
Repeated weekly cycles of CIE/AIR exposure were alternated with Test drinking weeks
when alcohol access was resumed as during Baseline.
In a separate experiment, independent cohorts of mice were similarly treated, but
sacrificed for Bdnf mRNA exon I, IV, and IX expression analysis at the end of baseline,
immediately following the 4th CIE/Air exposure cycle, and 24-hr after a 4th Test drinking
session (Figure 3.1).
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(x6)

CIE
or
AIR

2-hr EtOH drinking

Test (1)
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Figure 3.1 - Schematic of Experiment 3.
All mice had 6 weeks baseline access to alcohol (15% ethanol v/v) and water for 2-hr.
Mice in the exercise Group received 2-hr home-cage wheel access, 1-hr after alcohol
drinking. Groups were further divided and mice were placed in alcohol vapor or air
inhalation chambers (16-hr/day for 4 days) during each weekly exposure cycle. Exercising
mice resumed wheel access (2-hr/day) during Test weeks.

82

Chronic Intermittent Ethanol (CIE) Exposure
Mice were exposed to chronic intermittent alcohol (ethanol) vapor or air in inhalation
chambers, as previously described (154, 157, 167, 168). Prior to each day of alcohol
vapor exposure, mice were administered 1.6 g/kg alcohol with 1 mmol/kg pyrazole in
saline, to stabilize blood ethanol concentration (BEC). Air exposed mice received only
pyrazole in saline. Alcohol and pyrazole were administered intraperitoneally (ip.) in a
volume of 0.02 mL/g body weight. Mice were placed in alcohol vapor or air inhalation
chambers (60x36x60 cm Plexiglas boxes) 16-hr/day for 4 days during each weekly
exposure cycle.
Using an air stone, alcohol (95% ethanol) was vaporized, mixed with fresh air and
delivered to the alcohol chamber. Air alone was delivered to the air chambers. The
concentration of alcohol in the chambers were monitored daily, and air and alcohol flow
rates were adjusted to maintain BECs in the 200-250 mg/dl range throughout cycles of
exposure. BECs were determined as previously described (154, 157, 168). Briefly, blood
was collected from the retro-orbital sinus using heparinized capillary tubes and assayed
using an Analox Instrument analyzer.
Brain Tissue Collection
Mice were sacrificed by decapitation and brains rapidly removed. The medial
prefrontal cortex (mPFC) and dentate gyrus region of the hippocampus (HPC) were
dissected on ice using 1-mm microdissection punches, with the mouse brain atlas serving
as a guide (480). Tissue samples were placed into RNA Later (Thermo Fisher; cat no.
AM7021). Total RNA was extracted from the brain tissue samples using ReliaPrep RNA
extraction kit (Promega; cat no. Z6012) according to the manufacturer’s instructions. Total
RNA was quantified on a Denovix DS-11FX spectrophotometer.
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qRT-PCR
Quantitative real time-polymerase chain reaction (qRT-PCR) assays were
performed using similar procedures to those previously published by our group (178). For
Bdnf exon I, IV, and IX mRNA measurements, cDNA was created using QuantiTect
Reverse Transcription Kit (Qiagen; cat no 205314) according to manufacturer’s
instructions. Custom designed TaqMan qRT-PCR primers were used to specifically target
and amplify Bdnf exon (I, IV, IX) mRNA, were designed using Integrated DNA
Technologies (IDT) primer designer online software and manufactured by Life
Technologies

(BDNF

I,

Forward:

GATGCCAGTTGCTTTGTCTTC;

Reverse:

CCACCACTTGGTGTGACTTAT; Probe: TCGCCAAGGTGGATGAGAGTTGAA; BDNF
IV,

Forward:

GCCTAGATCAAATGGAGCTTCT;

Reverse:

GCCGATATGTACTCCTGTTCTG; Probe: ACCTCCGCCATGCAATTTCCACTA; BDNF
IX,

Forward:

GTGACAGTATTAGCGAGTGGG;

GGGATTACACTTGGTCTCGTAG;

Probe:

Reverse:

CAGTTGGCCTTTGGATACCGGGA).

Cyclophilin (Ppia) (Life Technologies) was used as the reference gene, for data
normalization. For the reactions, 10 µl of sample cDNA and TaqMan Universal Master Mix
II, with UNG (Applied Biosystems; cat no 4440042), were loaded in triplicate into a 384well optical PCR plate and analyzed on a BioRad CFX384 Real Time PCR system. Cycling
parameters: 50° C for 2-min, 95° C for 10-min, followed by 40 amplification cycles with
melting at 95° C for 15-sec, and annealing/extending at 60° C for 60 sec. Fluorescence
readings are obtained after each cycle. The 2^-DDCT method (481) was used to
calculated fold change in expression of the target gene relative to the reference gene
(Ppia) using the CTL group as the reference condition.
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Statistical Analysis
All statistical analyses were performed using SPSS Statistics version 25 with
significance set at p<0.05. Exercise measured as running distance (km) was averaged
over the last seven days of Baseline and analyzed by one-way ANOVA with Group as the
factor. Weekly body weight (gm), was analyzed by Repeated Measures ANOVA, using
Exercise and Group as between-subjects factors and Week as a within-subjects factor.
Repeated measures ANOVA was performed on weekly average alcohol intake (g/kg), with
Exercise and Group as between-subjects factors and Week as a repeated measure. Bdnf
mRNA (fold change) was analyzed by two-way ANOVA (Exercise x Group factorial).
Separate analyses were conducted for Bdnf mRNA for exon I, IV, and IX. Pairwise
comparisons with Bonferonni corrections were performed when appropriate.
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Results
Exercise (Wheel-Running) Attenuates CIE-induced Escalated Alcohol Intake
The effects of exercise (wheel-running) on alcohol drinking was determined in
dependent (CIE-exposed) and nondependent (Air-exposed) mice. During the Baseline
phase of the study, stable levels of running were established (Figure 3.2), with no
differences seen between groups (WH-Air: 2.11 ± 0.20 km, WH-CIE: 2.39 ± 0.13 km). This
was confirmed by repeated measures ANOVA, which indicated that wheel-running during
the last seven days of Baseline did not differ between groups [Group x Day interaction:
F(1,18) = 1.535, p=0.232]. Although Group was a pseudo-variable at this point in the
experiment, these results indicate that the groups had similar exercise history prior to
CIE/Air exposure.
Mice with access to a running wheel evidenced lower body weights (Figure 3.3),
with a significant difference between exercise and sedentary mice being detected by
repeated measures ANOVA [Exercise: F(1, 37) = 9.034]. Within-subjects effect of Week
[F(5, 185) = 139.593, p<0.005] and a Week x Exercise interaction [F(5, 185) = 37.713,
p<0.005] indicate mice gain weight over time and Weeks 3-6 sedentary mice weigh more
than exericse mice (ps<0.02). Main effect of Group [F(1,39)= 8.77, p<0.005].
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Figure 3.2 - Experiment 3: Daily Baseline Wheel Running.
Average daily running (km) at Baseline for mice that will be exposed to Air or CIE vapor.
No differences between groups at Baseline over the last 7 days of running. Values are
mean ± s.e.m (p=0.23; N=9-10/group)
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Figure 3.3 - Experiment 3: Average Weekly Body Weights
Average Group body weights (g) for exercising (WH) and sedentary mice (NWH) during
Baseline. Values are mean ± s.e.m. (N= 9-11/group). Group x Week interaction (p<0.005),
pair-wise comparisons (Exercise: No Wheel x Wheel, *p<0.02).
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Wheel running distance (km) was determined over the last week of Baseline and 4
Test weeks for CIE and Air groups (Figure 3.4). Exposure to alcohol vapor on the whole
resulted in reduced running compared to Air exposure. Repeated measure by Week of
average distance ran during Baseline and Test 1-4 indicates a main effect of Group [F(1,
17) = 4.052, p=0.06] and a Group x Week interaction [F(4,68) =7.21, p<0.0005]. Pairwise
comparisons reveal no Group (WH-Air vs WH-CIE) differences during the last 9 days of
Baseline [F(1, 17) = 0.415, p=0.528], Test 1 [F(1, 17) = 1.002, p=0.331] or Test 2 [F(1, 17)
= 2.194, p=0.157]. Significant Group differences were detected Test 3 [F(1, 17) = 9.408,
p<0.007] and Test 4 [F(1, 17) = 8.105, p<0.011]. This data indicates that CIE exposure
decreases wheel running activity, which worsens with repeated CIE exposures.
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Figure 3.4 - Experiment 3: Wheel Running During Test Weeks.
Average daily running (km) of mice exposed to Air or CIE vapor. Values are mean ± s.e.m.
Main effect of Group (*p<0.05; N=9-11/group).
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As previously observed (Chapter 2), there was a small but significant increase in
alcohol consumed in WH mice compared to NWH mice beginning at Week 3 during the
Baseline period (Figure 3.5A). This was supported by ANOVA that revealed a main effect
of Exercise [F(1, 37) = 28.077, p<0.005]. A significant Exercise x Week interaction [F(5,
185) = 9.761, p<0.005] followed by pairwise comparisons indicated WH mice consumed
more alcohol than NWH mice during Weeks 3-6 (ps<0.005). Main effect of Group
[F(1,37)= 0.22, p=0.64], and interactions of Group x Exercise x Week [F(5,185)= 1.2,
p=0.31], Group x Exercise [F(1,37)= 0.14, p=0.71], and Group x Week [F(5,185)= 0.13,
p=0.99] were not significant as at Baseline. Group was a pseudo-variable, indicating that
Exercise mice had similar alcohol drinking history prior to being separated for CIE/Air
exposure.
Due to lower body weights of exercising mice, volume (ml) of alcohol intake was
also analyzed (Figure 3.5B). Similar to alcohol intake (g/kg), ANOVA revealed a significant
main effect of Exercise [F(1,35)= 7.32, p<0.02], indicating greater alcohol intake in WH
compared to NWH mice. ANOVA also indicated a main effect of Week [F(5,175)= 98.68,
p<0.0005] and an Exercise x Week interaction [F(5,175)= 6.29, p<0.005]. Pairwise
comparisons indicated that wheel access increased alcohol intake during Week 3
(p<0.05), Week 4 (p<0.02), Week 5 (p<0.001), and Week 6 (p<0.0005). As seen with g/kg
intake, no significant main effect of Group [F(1,35)= 0.08, p=0.8] or significant interactions
were detected between Group x Exercise x Week [F(5,185)= 1.11, p=0.71], Group x
Exercise [F(1,37)= 0.86, p=0.36] and Group x Week [F(5,185)= 0.26, p=0.94]. Baseline
Group was a pseudo-variable, indicating that Exercise mice had similar alcohol drinking
history prior to CIE/Air exposure.
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Figure 3.5 - Experiment 3: Baseline Alcohol Consumption.
Average weekly alcohol intake in A) g/kg, Exercise x Week interaction (*p<0.005) and B)
mL, Exercise x Week l interaction (*p<0.05). Values are mean ± s.e.m. (N= 9-11/group).
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Following 6 weeks of baseline, mice were exposed to 4 cycles of alcohol vapor
(CIE) or air (Air), interleaved with weeks of Test drinking. Exercise (wheel-running)
significantly attenuated CIE-induced escalated alcohol intake (g/kg) (Figure 3.6A).
ANOVA indicated significant main effects of Group [F(1, 33) = 62.38, p<0.0005] (CIE>Air)
and Exercise [F(1, 33) = 7.95, p<0.008] (NWH>WH), as well as a significant Exercise x
Group interaction [F(1,33) = 12.12, p<0.001]. Pairwise comparisons with Bonferonni
correction revealed significant differences between NWH-Air vs. NWH-CIE, WH-Air vs.
WH-CIE, and NWH-CIE vs. WH-CIE groups (ps<0.005). ANOVA also revealed significant
Exercise x Week [F(3, 99) =2.59, p=0.057] and Group x Week [F(3, 99) =4.313, p<0.007]
interactions, but the Exercise x Group x Week interaction was not statistically significant
[F(3, 99) =1.07, p=0.37].
Because alcohol intake between exercised (WH) and sedentary (NWH) mice was
different at Baseline (Figure 3.5A & B), alcohol consumption was also expressed and
analyzed as percent change from respective baseline levels for each group (Figure 3.6B).
ANOVA indicated significant main effects of Group [F(1, 33) = 45.67, p<0.0005] and
Exercise [F(1, 33) = 85.74, p<0.0005], and the Group x Exercise interaction [F(1, 33) =
11.11, p<0.002]. Pairwise comparisons reveal significant differences between NWH-CIE
vs. NWH-Air, WH-CIE vs. NWH-CIE, WH-Air vs. NWH-Air (ps<0.0005), and WH-CIE vs.
WH-Air (p<0.019) groups. While there was a Group x Week interaction [F(3,99) =4.31, p
=0.007] there was not a significant Group x Exercise x Week interaction [F(3,99) =1.3,
p=0.28]. Collectively, these data indicate that daily limited access to wheel-running
significantly reduced the capacity from CIE exposure to escalate voluntary alcohol
consumption.
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Figure 3.6 - Experiment 3: Test Alcohol Drinking.
Average weekly intake in A) g/kg, Group x Exercise interaction (p<0.001) and B) percent
change from baseline, Group x Exercise interaction (p<0.002). Values are mean ± s.e.m.
(N=9-11/group). Significantly differs from NWH-Air group (*p<0.005), from NWH-CIE
(+p<0.005), from WH-Air (^p<0.005), main effect of Exercise (~p<0.005).
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Exercise Blocks CIE-induced Reductions of Bdnf mRNA in mPFC
To determine the effects of exercise on Bdnf mRNA expression in mPFC, separate
cohorts of mice were treated as described above, but they were sacrificed at the end of
Baseline, immediately following the 4th CIE/Air exposure cycle, or the end of the 4th Test
week (see Figure 3.1). Bdnf exon I, IV, and IX mRNA were analyzed separately at each
time point by ANOVA.
Analysis of Bdnf mRNA expression in mPFC tissue 24-hr after the final 2-hr running
session during Baseline conditions (Figure 3.7A) indicated that exercise produced
significant increases in Bdnf exon I [F(1,18) = 8.59, p<0.009] and exon IV mRNA [F(1,
18) = 4.89, p<0.05], with a trend toward an increase in exon IX expression [F(1, 18) =
3.75, p=0.07] compared to sedentary (No Wheel) mice.
A cohort of mice exposed to 4 cycles of CIE or Air vapor, with or without exercise
was sacrificed immediately out of chambers at the end of their last exposure cycle. Bdnf
mRNA was analyzed by qPCR (Figure 3.7B) and demonstrated the ability of wheel running
to increase Bdnf mRNA and prevent reductions induced by CIE exposure. Two-way
ANOVA shows a main effect of Group for exon I [F(1,33) =7.12, p<0.012], exon IV [F(1,35)
=10.73, p<0.002], and exon IX [F(1,34) =18.98, p<0.0005]. In addition there was a main
effect of Exercise exon I [F(1,33) =11.65, p<0.002], exon IV [F(1,35) =13.68, p<0.001],
and exon IX [F(1,34) =17.36, p<0.0005]. Although there were no significant Group x
Exercise interactions for either exon I [F(1,33) =1.33, p=0.26], exon IV [F(1,35) =0.18,
p=0.69], or exon IX [F(1,35) =0.04, p=0.84] this data does indicates exercise is capable of
mitigating reductions in mPFC Bdnf mRNA caused by repeated cycles of chronic alcohol
vapor.
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Following a 4th Test week Exercise increased Bdnf exon I mRNA (Figure 3.7C)
indicated by ANOVA. Analysis revealed a main effect of Exercise [F(1,33) = 17.67,
p<0.005] and a trend toward a Group x Exercise interaction [F(1,33) = 3.74, p=0.062].
Based on the trend for the interaction and a visual inspection of the graph, post-hoc
comparisons were performed. Post-hoc comparisons reveal a significant difference
between CIE groups in the Exercise condition (NWH-CIE<WH-CIE, p<0.005) and between
nonrunning mice in the Group condition (NWH-CIE<NWH-Air, p<0.04). The factor Group
was not significant [F(1,33) =1.59, p=0.22]. Taken together these data indicate CIE
exposure can produce prolonged reductions of exon I mRNA which are reversed by
exercise.
Exon IV showed no Group x Exercise interaction [F(1, 35) =3.14, p=0.09], main
effect of Group [F(1, 35) =0.054, p=0.82] or main effect of Exercise [F(1, 35) =1.34, p=0.26]
on exon IV mRNA levels.
Exon IX mRNA displayed a recovery in expression following CIE exposure. Both
NWH- and WH-CIE groups demonstrated significant increase in expression increase in
expression of CIE exposed mice, indicated by a between-subjects main effect of CIE [F(1,
32) =6.59, p<0.02].
After a 4th Test week, qRT-PCR analysis evidenced wheel running increased Bdnf
exon I indicated by a main effect of Exercise [F(1,33) = 17.67, p<0.005] (Figure 3.7C).
While no main effect of Group emerged [F(1,33) =1.58, p=0.22] trend toward a Group x
Exercise interaction was detected [F(1,33) = 3.74, p=0.062].
Based on the data and the trend toward an interaction, post-hoc comparisons were
performed, revealing alcohol dependent sedentary mice had lower Bdnf exon I mRNA
expression than alcohol dependent mice that exercised (NWH-CIE < WH-CIE; p<0.005)
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and air exposed sedentary mice (NWH-CIE < NWH-Air; p<0.04). This data indicates wheel
running can reverse CIE-induced reductions of exon I in the mPFC.
Analysis of Bdnf exon IV mRNA levels showed no effect of Group [F(1, 35) =0.054,
p=0.818], Exercise [F(1, 35) =1.336, p=0.256] or Group x Exercise interaction [F(1, 35) =
3.139, p=0.085]. Exon IX mRNA displayed a recovery in expression following CIE
exposure, regardless of access to a running wheel, indicated by a main effect of CIE [F(1,
32) =6.59, p<0.02]. No effect of Exercise [F(1,32) =0.86, p=0.36] or Group x Exercise
interaction [F(1,32) = 0.075, p=0.79] were observed.
These results replicate previous findings validating the ability of wheel running to
elevate Bdnf mRNA in the mPFC after several weeks of wheel access, while also
demonstrating the ability of wheel running to protect against CIE-induced reductions in
Bdnf mRNA in the mPFC.
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Figure 3.7 - Experiment 3: Bdnf mRNA Expression in the mPFC.
Bdnf mRNA fold change in exercising (WH) and sedentary (NWH) mice exposed to Air or
CIE vapor at (A) the end of Baseline (B) immediately out of a 4th CIE/Air exposure cycle
(0-hr) and (C) 24-hr after a 4th Test drinking week. Values are mean ± s.e.m. Expression
fold change relative to NWH-Air group. Main effect of Exercise (^p<0.05); main effect of
Group (*p<0.05), compared to NWH-CIE (+p<0.05), compared to NWH-Air (#p<0.05).
N=7-10/group.
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Discussion
Exercise is being used as an adjunct strategy in the treatment of drug and alcohol
abuse and addiction (138, 139, 234-236). In this chapter we explored the ability of
exercise, in the form of limited access voluntary wheel running, to attenuate the
development of alcohol dependent-related escalated alcohol intake. We replicated finding
from Chapter 2 showing 2-hr/day wheel access caused stable levels of running over
several weeks reduced body weight, increased baseline levels of alcohol intake, and
increased Bdnf mRNA in the mPFC of mice. We further show the ability of exercise (wheel
running) to attenuate the escalation of alcohol intake and prevent reductions of Bdnf
mRNA in the mPFC induced by an alcohol dependence model.
With only three FDA approved medications, alternative targets and therapies for the
treatment of AUD are needed. One possible target is the BDNF-TrkB system as data
shows an inverse relationship between BDNF-TrkB signaling and alcohol intake (299303). CIE-exposed mice have decreased Bdnf mRNA and protein expression in the mPFC
and increasing BDNF in this region blocked escalated alcohol drinking (174, 178, 326).
Exercise has multiple health benefits including naturally increasing BDNF expression
(137, 340, 349). Making the BDNF-TrkB system a reasonable target and exercise a
potential therapeutic for alcohol dependence.
Mice exposed to repeated cycles of CIE vapor escalate their voluntary alcohol intake
compared to their Baseline and compared to Air-exposed control mice (154, 157, 172,
174, 178, 326). Here, we demonstrated wheel running could blunt the escalation of alcohol
intake, even after multiple CIE exposures. Replicating results from Chapter 2, running
mice, even though they weighed less, consumed not only greater amounts of alcohol
(ethanol; g/kg) but also drank a larger volume (mL). Due to these differences in alcohol
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intake data was expressed as a percent change from Baseline intake. This allows for the
assessment of how exercise affects the escalation of alcohol intake. Adjusting for Baseline
differences, nonrunning mice exposed to chronic alcohol vapor robustly escalated their
alcohol intake during each Test week. This effect was severely attenuated in mice with
access to a running wheel. To our knowledge, this is the first-time exercise has been
shown to reduced alcohol drinking in a rodent model of dependence.
Current data available describing the effects of exercise on alcohol drinking behavior
in rodents is sparse, with most work focusing on nondependent drinking (136, 223, 235,
487). In this limited literature results have been mixed with increases, decreases, and no
changes in alcohol consumption being detected. The different results are most likely due
to variations in methodologies, species, and strains.
Our results indicate that exercise provides a protective mechanism to treat alcohol
dependence related drinking by attenuating the escalation in alcohol intake. No data is
currently available in regard to the effects of exercise on alcohol dependence related
drinking however, data exists for other drugs of abuse. These studies provide evidence
that wheel running will reduce self-administration of nicotine, methamphetamine, cocaine,
and opioids (231, 236-243). Not only did aerobic exercise reduce drug intake but
resistance training in rats decreased cocaine and heroin self-administration (242, 243).
Human literature provides further support/confirmation of exercise’s potential to treat AUD.
Detoxified alcoholics who participated in low or moderate intensity exercise had a reduced
urge to drink and when they did drink, they consumed less alcohol (228, 229). Similar to
our results in mice, nondependent, adult humans who exercise consume greater levels
alcohol than those that do not but also display a blunting in the development of alcohol
abuse and dependence (240-243, 245-247). The increase in alcohol drinking at baseline
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in exercising mice may create a ceiling effect, obscuring any escalations in alcohol intake.
Additionally, for better comparisons between groups data should be adjusted to a percent
change from baseline, to account for these baseline differences.
Evidence establishes an inverse relationship between Bdnf mRNA and BDNF
protein levels in the mPFC and alcohol drinking behavior (174, 178, 325, 486). Our lab
has shown a reduction in BDNF in the mPFC after repeated cycles of CIE exposure which
can be blocked by replenishing or over-expression BDNF (mRNA and protein) in this
region (174, 178, 486). Here, we replicated these finding demonstrating repeated cycles
of CIE-exposure reduces Bdnf mRNA expression in the mPFC (174, 178, 486) and
running at baseline (nondependent) increased expression in this same region (see
Chapter 2). Excitingly, in addition to exercise’s effect on the attenuation of escalated
alcohol intake, we show mice that exercise can prevent reductions of Bdnf mRNA in the
mPFC caused by heavy alcohol exposure. Thus, indicating a mechanism in which
exercise functions in the treatment and prevention of AUD. Increased Bdnf mRNA, as a
result of exercise, prior to heavy alcohol exposure, may function as a buffer to prevent or
delay the development of AUD, thereby acting as a protective mechanism. Additionally,
exercise after heavy alcohol exposure may serve to speed the rate of BDNF production to
recover lost BDNF and begin to counteract the negative effects alcohol has on neuronal
function and health.
One limitation to consider is BDNF protein was not analyzed in these samples due
to lack of tissue being available. While we demonstrated in Chapter 2 that exercise
increased both Bdnf mRNA and BDNF protein in the mPFC, and it is established that CIE
exposure reduces both Bdnf mRNA and BDNF protein (174, 178, 486) we do not know if
Bdnf mRNA and BDNF protein levels correlate in wheel running CIE exposure mice.
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Evidence exists that BDNF protein can be trafficked to the mPFC from the HPC (492) and
BDNF originating in the mPFC can be trafficked to the NAc (267, 268), thus Bdnf mRNA
expression measured in the mPFC may not directly correlate with protein expression in
this region depending on trafficking.
Occurring predominately in the early portion of the later Test weeks, repeated cycles
of alcohol vapor exposure caused mice to run less than those exposed to air. Running
activity progressively recovered throughout the week. Although we demonstrated mice
which exercise attenuated alcohol intake after alcohol vapor exposure, it is unknown
whether a history of wheel running is necessary or if acute exercise is sufficient to blunt
intake during Test weeks. In Chapter 2 we replicated demonstrating 2-days of 2-hr
running, after a period of inactivity, was able to rapidly elevate Bdnf mRNA and protein in
these mice with a history of exercise (137). If the beneficial effect of exercise is through
an acute increase of BDNF expression, proximal to CIE exposure, it may be critical for
mice to have a “primed” BDNF system (137), allowing for rapid increases in BDNF
expression. That is, does a history of running and BDNF elevation protect against alcohol
dependence and how long does this effect last with repeated cycles of CIE? Or is it
necessary for exercise to be introduced immediately after a heavy alcohol exposure in
order to attenuate CIE-induced increases in alcohol intake?
The reduction in wheel activity is most likely due to early withdrawal effects of CIE
vapor exposure. Acute withdrawal from heavy alcohol exposure produces negative
affective states that include anxiety, depression, and anhedonia which will drive craving
and relapse (11, 66-68). As with a human suffering from negative physical withdrawal
effects, mice will be less likely and motivated to participate in physical activity. If a
minimum amount of exercise needs to be performed after CIE exposure to increase Bdnf
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mRNA expression, deficits in running activity early in the Test week may be detrimental to
the beneficial effects of exercise.
Additionally, exercise prevents CIE from decreasing Bdnf mRNA in the mPFC and
engenders an increase in Bdnf mRNA to prior to alcohol vapor exposure levels. Thus,
providing a potential mechanism for exercise to exert its benefits in the treatment of AUD.
In this Chapter we add to previously published findings showing CIE exposure, with
interleaved alcohol drinking Test weeks, caused reductions of Bdnf mRNA in the mPFC
of mice (178, 486). Here, it is revealed that wheel access prior to CIE-exposure prevented
significant reductions in Bdnf mRNA in the mPFC and goes further to demonstrate wheel
access during Test weeks will re-elevate Bdnf mRNA in this region and that these mice
do not show as robust of an escalation of alcohol intake after CIE exposure. This
information taken with published data revealing reduced Bdnf mRNA and protein,
specifically in the mPFC, can lead to increased alcohol intake and that preventing these
reductions can treat escalated alcohol intake (174) indicates a potential mechanism for
exercise to attenuate CIE-induced escalated alcohol drinking. Here, we describe a role of
exercise to prevent reductions in BDNF caused by alcohol vapor exposure and to
attenuate escalated alcohol drinking, suggesting that wheel running can prevent increased
drinking through elevations in BDNF.
In summary, mice that exercise display an attenuated response to chronic alcohol
vapor exposure, mitigating the effects on reducing Bdnf mRNA in the mPFC and blunting
the escalation of alcohol intake.
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Chapter 4 - Role of BDNF-TrkB Signaling in the
Effects of Exercise (Wheel-Running) on Alcohol
Drinking in Dependent and Nondependent Mice
Introduction
Repeated bouts of heavy alcohol use and abstinence can lead to alcohol
dependence, which is characterized by dysregulation of multiple neurotransmitter and
neuropeptide systems in the brain (43, 44, 493, 494). Targeting these systems
pharmacologically, to restore balance and function, is a means of treating excessive
alcohol consumption. Unfortunately, there are only two FDA-approved medications
(naltrexone and acamprosate) that target such adaptations (the third medication,
disulfiram, influences alcohol metabolism) [51, 55, 77, 174, 180, 183]. As these treatments
are not sufficiently effective (29-31), new targets for the treatment of alcohol dependence
are being explored. One potential target is brain-derived neurotrophic factor (BDNF), as
reduced BDNF expression in brain has been shown to be associated with alcohol
dependence and increased alcohol drinking (318, 319).
As previously described, BDNF is a member of the neurotrophin family that binds
predominantly to TrkB receptors [260]. A complex gene structure comprised of nine
different exons, with exon IX coding for the BDNF protein and the other eight exons being
differentially spliced to exon IX acting as promoter sequences (257). Through downstream signaling, BDNF regulates growth, differentiation, and maintenance of neurons
[246]. Roles in complex behaviors such as learning and memory [246, 247],
neuropsychiatric disorders, and addiction [203-208]. Binding with its primary receptor
target, tropomyosine-related kinase-B (TrkB) receptors, BDNF causes dimerization of the
receptor and activation of one of three signaling cascades: PI3K, PLC-gamma, or the MAP
kinase pathway (272). Global inhibition of brain TrkB activity is associated with elevated
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alcohol consumption (178, 317, 320, 326, 486) and direct infusion of BDNF into this region
blocks dependence-related escalated alcohol intake (174). Additionally, viral-mediated
over-expression of BDNF in the mPFC prevented the emergence of excessive drinking in
a model of alcohol dependence (174). Collectively, these data provide a strong basis for
targeting the BDNF system in the treatment of alcohol dependence and excessive
drinking.
It is well established that aerobic exercise increases Bdnf mRNA and BDNF protein
expression in the brain (136-139, 221). Participation in exercise caused adolescents and
young adults to use less drugs and alcohol and reduced the urge to drink and the amount
consumed in detoxified alcoholics (231, 239-243, 247). In Chapter 3, we demonstrated
that daily scheduled aerobic exercise (wheel-running) in the home-cage attenuated
escalated drinking in mice following repeated cycles of chronic intermittent ethanol (CIE)
exposure. Further, we showed exercise prevented CIE-induced reductions in Bdnf mRNA
levels in the mPFC. This evidence demonstrates BDNF in the mPFC regulates alcohol
drinking, suggests that increased BNDF-TrkB receptor signaling may be an important link
between the effects of exercise and dependence-related excessive drinking.
In this chapter we aimed to examine this possibility by using a pharmacological
antagonist of TrkB receptors. determine if voluntary wheel running attenuates CIE-induced
escalated alcohol intake through BDNF-TrkB signaling. Specifically, we tested the
hypothesis that TrkB antagonism with ANA-12 (495) would prevent or reduce the ability of
exercise (wheel-running) to attenuate CIE-induced escalated alcohol drinking.

105

Methods
Subjects
Adult male C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME) were individually
housed under a 12-hr light/dark cycle (lights on at 8:00 AM). Mice were provided with food
(Teklad rodent diet) and water ad libitum in a temperature and humidity controlled
AAALAC-accredited facility at the Medical University of South Carolina. All procedures
were approved by the Institutional Animal Care and Use Committee and conducted in
accordance with the NIH Guide for the Care and Use of Laboratory Animals.

Experimental Design and Procedure
The study was performed in a balanced design of 2 (Exercise: Wheel, No-Wheel) x
2 (Group: CIE, Air) x 3 (Drug: Vehicle (1% DMSO in PBS), 0.5 mg/kg ANA-12, 1.0mg/kg
ANA-12) (N= 9-11/group). During a 6-week Baseline period, mice received home-cage
access to 1 bottle of alcohol (15% v/v ethanol) and 1 bottle of water, for 2-hr, starting 3-hr
into the dark cycle. Starting 1-hr after the drinking session, some mice (WH groups) were
given access to an activity wheel for 2-hr in their home cage. The remaining mice (NWH
groups) were left undisturbed during this exercise period. The 2-hr alcohol drinking
sessions occurred Monday – Friday each week and scheduled access to activity wheels
was provided 7 days/week. Following the Baseline period, mice received CIE or Air
exposure (16-hr/day for 4 days) in inhalation chambers, as described below. During
CIE/Air inhalation exposure, alcohol drinking and exercise were not available to mice.
Daily wheel-running (2-hr) resumed 24-hr after the final day of chamber exposure and
alcohol drinking sessions (2-hr) commenced 72-hr after CIE/Air exposure for a 5-day test
period (Test 1). Mice then received a 2nd CIE/Air exposure cycle before being were
separated into three drug treatment groups (Vehicle, 0.5 mg/kg, or 1.0 mg/kg ANA-12).
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During Test 2, ANA-12 (0.5 mg/kg or 1.0 mg/kg) or Vehicle was injected intraperitoneally
(ip.) immediately following the 2-hr wheel-running sessions. Treatment started following
the first day exercise commenced after the 2nd CIE/Air exposure cycle and continued for
6 days into Test 2 (Figure 4.1).

Chronic Intermittent Ethanol (CIE) Exposure
Mice were exposed to chronic intermittent ethanol vapor or air in inhalation
chambers, as previously described (154, 157, 167). Prior to each day of ethanol vapor
exposure, mice were administered 1.6 g/kg ethanol with 1 mmol/kg pyrazole in saline, to
stabilize blood ethanol concentration (BEC). Air-exposed mice received only pyrazole in
saline. Ethanol and pyrazole were administered intraperitoneally (ip.) in a volume of 0.02
mL/g body weight. Using an air stone, 95% ethanol was vaporized, mixed with fresh air,
and delivered to the alcohol chambers. Air alone was delivered to the air chambers. The
concentration of alcohol in the chambers were monitored daily, air and alcohol flow rates
were adjusted to maintain BECs in the 200-250 mg/dl range throughout cycles of exposure
(BECs were determined as previously described).

ANA-12 Preparation
The TrkB antagonist, ANA-12 (Selleckchem Cat no S7745), was resuspended in 1%
(DMSO) in phosphate-buffered saline (PBS) (Sigma Aldrich) at 0.1 mg/mL for 1 mg/kg
and 0.05 mg/mL for 0.5 mg/kg doses. ANA-12 (and vehicle) was administered
intraperitoneally (ip.) in a volume of 0.01 mL/g body weight.

107

2-hr EtOH drinking

72-hr EtOH Abstinence
CIE
or
AIR
Baseline (x6)

CIE
or
AIR
Test (1)

2-hr Wheel Access
Test (2)
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Figure 4.1 - Schematic of Experiment 4.
2 (Exercise: Wheel, No-Wheel) x 2 (Group: CIE, Air) x 3 (Drug: Vehicle (1% DMSO in
PBS), 0.5 mg/kg ANA-12, 1.0mg/kg ANA-12) (N= 9-11/group). All mice had 6 weeks of
Baseline Alcohol (15% v/v ethanol) drinking period. Exercise mice (WH-CIE, WH-Air) had
2-hr wheel access 1-hr after the drinking session. Following Baseline mice were exposed
to alcohol vapor (CIE) or air (Air) 16-hr/day x 4 days. During Test 2 mice were treated ip.
with ANA-12 (0, 0.5, or 1.0 mg/kg) immediately after wheel running.

108

Statistical Analysis
All statistical analyses were performed using SPSS Statistics version 25 with
significance set at p< 0.05. Average running distance (km) over the last 7 days of Baseline
was analyzed by one-way ANOVA with Group as the main factor. Weekly body weight
(grams) was analyzed by Repeated Measures ANOVA, with Exercise as the betweensubjects factor and Week as a within-subjects factor. Likewise, average weekly alcohol
intake (g/kg) during Baseline was analyzed by 2-way ANOVA (Exercise x Week). Average
alcohol intake during Test 1 (expressed as g/kg and percent change from baseline) was
analyzed by ANOVA, with Exercise and Group as between-subject factors. Similarly,
alcohol intake during Test 2 was analyzed by ANOVA, with Drug as an additional factor.
Pairwise comparisons with Bonferonni corrections were performed when appropriate.
During the Test weeks the average distance (km) mice ran was analyzed by repeated
measures ANOVA with CIE as the main factor. Weekly body weight (grams) was analyzed
by Repeated Measures ANOVA, using CIE and Group as the between-subjects factor and
Week as within-subjects factor. When applicable pairwise comparisons with Bonferonni
corrections were performed. Two-way ANOVA was performed on Baseline and Test 1
alcohol intake (g/kg and percent change). Between-subject factors were Wheel Running
and CIE/Air exposure with average weekly alcohol intake (g/kg) or percent change as the
independent variable. In Test 2 ANOVA was performed on alcohol drinking (g/kg and
percent change) with the Drug added as a between-subject factor. Pairwise comparisons
with Bonferonni corrections were performed when applicable.

109

Results
During the 6-week Baseline period, wheel-running behavior stabilized for all mice
and ANOVA revealed no significant difference in running distance between WH-CIE and
WH-Air groups over the last 7 days of Baseline (prior to inhalation treatment) [F(1,66)=
3.41, p= 0.07] (Figure 4.2).
As previously reported (Chapter 2 Figure 2.3 & 2.6, Chapter 3 Figure 3.3), mice with
access to activity wheels gained less weight than those not given an opportunity to
exercise over the Baseline period (Figure 4.3). ANOVA indicated a significant main effect
of Exercise [F(1,113)= 5.57, p< 0.02], and a significant Exercise x Week interaction
[F(6,68)= 23.10, p< 0.005]. Pairwise comparisons showed WH mice weighed significantly
less than NWH mice during Weeks 2-6 (ps< 0.05).
During Baseline, wheel-running mice displayed elevated alcohol consumption
compared to mice that did not have access to activity wheels (Figure 4.4). This was
supported by ANOVA, which indicated a significant main effect of Exercise [F(1,111)=
27.17, p< 0.005] and a significant Exercise x Week interaction [F(5,565)= 23.58, p< 0.005].
Pairwise comparisons indicated significant differences between Groups during Week 1
(p< 0.02) with the Exercise group consuming slightly less alcohol than sedentary mice and
Week 3-6 (ps< 0.005) where exercise modestly increased alcohol intake.

As

demonstrated in Chapters 2 and 3, the modest increase in alcohol intake was also seen
when milliliters of alcohol consumed was analyzed (data not shown).
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Figure 4.2 - Experiment 4: Daily Baseline Wheel Running.
Average daily running (km) at Baseline for mice to be exposed to Air or CIE vapor. No
differences between groups at Baseline over the last 7 days of running. Values are mean
± s.e.m (N=27-29/group).
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Figure 4.3 - Experiment 4: Weekly Baseline Body Weights.
Exercise (WH) resulted in lower body weight compared to sedentary mice (NWH). main
effect of Exercise (p<0.003). Values are mean ± s.e.m. (N=55-56/group). Significantly
differs from NWH (*p<0.05).
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Figure 4.4 – Experiment 4: Baseline Alcohol Intake.
Baseline, weekly average alcohol intake (g/kg) in exercising (WH) and sedentary (NWH)
mice. Exercise x Week Interaction (p<0.005) and main effect of Exercise (p<0.01). Values
are mean ± s.e.m. (N =55-56/group). Differs from NWH (*p<0.05).
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Exercise Attenuates Escalated Alcohol Intake
Analysis of alcohol intake (g/kg) during Test 1 indicated a significant Exercise x
Group interaction [F(1,111)= 7.65, p< 0.007] (Figure 4.5A). Pairwise comparisons
indicated all groups (WH-Air, NWH-CIE, WH-CIE) evidenced higher alcohol intake
compared to the NWH-Air group (ps< 0.05). Main effects of Group [F(1,111)= 33.24,
p<0.0005] and Exercise [F(1,111)= 12.8, p<0.001] we evidenced. Because exercise
altered alcohol intake during Baseline (Figure 4.4), alcohol intake data were expressed as
a percent change from baseline (Figure 4.5B), to determine how drinking behavior
changed relative to each animal’s individual baseline. Analysis of percent change data
revealed significant main effects of Exercise [F(1,111)= 12.80, p< 0.005] and Group
[F(1,111)= 33.24, p< 0.005]. Although Group x Exercise interaction was not significant
[F(1,111)= 2.46, p=0.12], alcohol intake was greater in NWH-CIE mice compared to NWHAir mice (NWH-CIE > NWH-Air; p<0.0005) and exercise was able to significantly attenuate
escalated intake (WH-CIE < NWH-CIE; p< 0.05). As such, these results replicate findings
observed in Chapter 3, demonstrating the ability of scheduled daily exercise to attenuate
CIE-induced escalated alcohol drinking.
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Figure 4.5 – Experiment 4: Test 1 Average Alcohol Intake
(A) g/kg intake at end of Baseline and Test 1. Baseline: main effect of Exercise (~p<0.05);
Test 1 Group x Exercise interaction (p<0.007). Significant compared to NWH-Air
(+p<0.005), compared to WH-Air (#p<0.05). (B) Percent change alcohol intake from
Baseline. Main effect Group (*p<0.005) and main effect of Exercise (^p<0.005). Values
are mean ± s.e.m. (N= 27-29/group).
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TrkB Antagonism Blocks the Attenuation of Escalated Alcohol Intake by Exercise
Analysis of alcohol intake (g/kg) during Test 2 indicated a trend toward an effect of
Exercise [F(1,103)= 3.52, p=0.64], a significant main effect of Group (CIE > Air) [F(1,103)=
73.24, p< 0.0005], and a Group x Exercise x Drug interaction [F(2,103)= 3.161, p< 0.05].
Pairwise comparisons of the interaction show the expected CIE-induced significant
increase in alcohol drinking in mice with no access to activity wheels (NWH-CIE > NWHAir), and this effect was not altered by ANA-12 treatment (all doses: ps< 0.001) (Figure
4.6A). Replicating our previous findings (Chapter 3), exercise attenuated CIE-induced
escalated drinking in vehicle-treated mice (NWH-CIE > WH-CIE = WH-Air = NWH-Air) (p<
0.05). However, this attenuating effect of wheel-running was blocked by ANA-12
treatment. That is, both doses of ANA-12 significantly increased alcohol intake in WH-CIE
mice compared to WH-Air mice (0.5 mg/kg: p< 0.0005; 1.0 mg/kg: p< 0.0005).
Furthermore, ANA-12 increased alcohol intake in WH-CIE mice compared to vehicletreated WH-CIE mice (Veh vs 0.5mg/kg: p< 0.016; Veh vs 1.0mg/kg: p< 0.013). No main
effect of Dose [F(2,103)= 0.53, p= 0.59] and interactions of Group x Exercise [F(1,103)=
0.5, p= 0.48], Group x Dose [F(2,103)= 1.12, p= 0.33] or Exercise x Dose [F(2,103)= 1.4,
p= 0.25] were detected.
Alcohol consumption during Test 2 expressed as a percent change from baseline is
shown in Figure 4.6B. Analysis of these data revealed main effects of Group [F(1,103)=
59.1, p< 0.0005] and Exercise [F(1,103)= 27.57, p< 0.0005], but no effect of Dose [2,103)=
0.8, p= 0.45]. Interactions were nonsignificant for Group x Exercise [F(1,103)= 0.054, p=
0.82], Group x Dose [F(2,103)= 0.4, p= 0.67] and Exercise x Dose [F(2,103)= 2.18, p=
0.12]. However, a significant Exercise x Group x Drug interaction [F(2,103) = 3.56, p<
0.05] was detected. Post-hoc analyses indicated that a history of CIE exposure
significantly increased alcohol drinking in mice that did not have access to activity wheels
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in their home-cage (NWH-CIE groups) compared to NWH-Air mice, and this was true for
all ANA-12 treatment conditions (Veh: p< 0.0005; 0.5 mg/kg ANA-12: p< 0.001; 1.0 mg/kg
ANA-12: p< 0.04). In vehicle-treated mice, wheel-running prevented CIE-induced
escalation of alcohol consumption (WH-CIE < NWH-CIE , p< 0.005). Of note, this
attenuating effect of exercise was reversed by ANA-12 treatment. That is, despite having
access to activity wheels, ANA-12 treated mice showed CIE-induced elevated alcohol
intake (Veh: NWH-CIE > WH-CIE , p< 0.05; 0.5 mg/kg ANA-12: NWH-CIE = WH-CIE, p=
0.09; 1.0 mg/kg ANA12: NWH-CIE = WH-CIE, p= 0.83). Additionally, alcohol intake was
significantly greater in WH-CIE groups that received 0.5 or 1.0 mg/kg ANA-12 compared
to WH-CIE mice injected with vehicle (ps< 0.05).
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Figure 4.6 – Experiment 4: Test 2 Average Alcohol Intake
Test 2 average alcohol intake of CIE/Air exposed mice treated with vehicle or ANA-12 (0.5
or 1.0 mg/kg). (A) g/kg intake, Group x Exercise x Drug interaction (p<0.05). (B) Percent
change alcohol intake from Baseline Group x Exercise x Drug interaction (p<0.05). Values
are mean ± s.e.m. (N= 12-15/group). Significant compared to NWH-Air (+p<0.005),
compared to WH-Air (^p<0.005), compared to NWH-CIE (%p<0.05), compared to Vehicle
treated WH-CIE (>p<0.05).
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Discussion
Exercise has shown efficacy in prolonging abstinence, reducing craving, and
decreasing alcohol intake (138, 139, 231, 240-243, 267, 268). Using the CIE mouse model
of alcohol dependence and relapse drinking, exercise was shown to attenuate escalated
alcohol intake in dependent mice (Chapter 3). Further, daily scheduled limited access to
activity wheels was shown to increase Bdnf mRNA (Chapters 2 and 3) and protein
(Chapter 2) expression in the mPFC. Since CIE-induced elevated drinking is associated
with reduced Bdnf mRNA and protein expression in the mPFC (174, 178, 325, 326), it was
hypothesized that exercise may attenuate dependence-related excessive alcohol
consumption by reversing reductions of BDNF activity in the mPFC following CIE
exposure. To address this research question, a pharmacological antagonist of TrkB
receptors, ANA-12, was administered in the model. Results from this study demonstrate
that ANA-12 treatment blocked the ability of exercise (wheel-running) to reduce CIEinduced escalated alcohol drinking. As such, these results implicate a role for exerciseinduced BDNF (possibly in the mPFC) in the reduction of alcohol intake in a model of
alcohol dependence.
Mice with no opportunity to exercise showed the expected CIE-induced increased
in alcohol drinking during Test 2, and this effect was not altered by ANA-12 treatment.
Since CIE exposure reduces BDNF expression in brain, it may be that already depressed
levels of BDNF masked any effects of ANA-12 in reducing BDNF-TrkB receptor signaling.
In addition, ANA-12 treatment did not alter drinking in nondependent (NWH-Air) mice. It
was previously shown that increasing BDNF levels in the mPFC (either by direct infusion
or viral-mediated over-expression) did not alter drinking in nondependent mice but
reduced intake in dependent animals (174). Thus, it may be that BNDF signaling in the
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brain (mPFC) may be more effective in modulating alcohol consumption under conditions
that engender excessive levels if intake. Support for this view comes from the fact that
exercise does not appear to alter drinking in nondependent mice, and ANA-12 treatment
did not affect alcohol drinking in nondependent exercising mice (WH-Air).
Confirming previous results obtained in Chapter 3, limited daily exercise (wheelrunning) attenuated CIE-induced escalated drinking. Of significance, ANA-12 treatment
blocked this effect. Both doses of ANA-12 tested were equally effective in reversing the
ability of exercise to reduce CIE-induced excessive drinking This provides support for the
hypothesis that exercise reduces CIE-induced excessive drinking by enhancing BDNF
expression and signaling in brain. Studies have implicated mPFC BDNF activity in the
regulation of alcohol dependent drinking mPFC (174, 178, 325).
While results from the present study demonstrate a potential role for BDNF-TrkB
receptor signaling in the ability of exercise to modulate dependence-related drinking, one
limitation to note is that the TrkB receptor antagonist was systemically administrated,
thereby limiting the ability to establish if these effects are mediated in the mPFC. Future
studies that directly manipulate BDNF-TrkB receptor signaling in the mPFC will help
address this issue.
While the present study implicates a role for BDNF-TrkB receptor signaling in the
effects of exercise on dependence-related alcohol drinking, the mechanism by which
exercise modulates BDNF expression and activity in brain is not fully understood. Though
BDNF can induce its own expression through TrkB receptor activation (272, 275), exercise
can increase BDNF expression through two possible mechanisms, beta-hydroxybutyrate
and irisin/FNDC5 (298, 299, 359, 367). Both of these mechanisms involve the metabolism
of fat in the body to generate metabolites which function to stimulate the production of
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BDNF in the brain. It has been suggested that exercise functions to prime the BDNF
system (137), allowing for rapid increases in BDNF expression and TrkB signaling. This,
in turn, may serve to mitigate deficits in BDNF activity that result from chronic alcohol (CIE)
exposure and, thereby, temper excessive levels of drinking.
In summary, results from the present study demonstrate that exercise (wheelrunning) is effective in attenuating escalated drinking associated with dependence. This
effect was reversed by TrkB receptor antagonism. Taken together, these findings support
a potential therapeutic effect of exercise in controlling alcohol consumption and implicate
BDNF-TrkB receptor signaling as a target for the treatment of alcohol addiction.
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Chapter 5 - General Discussion and Future
Directions
Alcohol addiction is a health crisis affecting 16 million Americans every year,
resulting in tens of thousands of deaths and injuries (1). The lack of fully efficacious
pharmacological agents and treatments for alcohol use disorder (AUD) (30, 31)
necessitates a strong need for additional pharmacological targets and therapeutic tools to
improve treatment outcomes. Exercise is one such strategy showing promise in the
treatment of neuropsychiatric conditions, including alcohol addiction (241-247).
An inverse correlation exists between alcohol consumption and brain-derived
neurotrophic factor (BDNF) expression (mRNA and protein). Specifically, in the medial
prefrontal cortex (mPFC), where reduction of BDNF expression and BDNF-TrkB signaling
results in increased alcohol intake (174, 325). Elevating BDNF in the mPFC, by direct
BDNF infusion or viral-overexpression, reversed or prevented escalated alcohol intake
(174). Thus, demonstrating a role of prefrontal cortical BDNF in the treatment of alcohol
use disorders.
Exercise naturally increases Bdnf mRNA and protein expression in the brain of
rodents and in the blood of humans (136, 137, 221, 298, 341), making it a promising AUD
treatment adjunct which can target the BDNF-TrkB system. Additionally, exercise can be
easily implemented in a clinical or home setting and is of no monetary cost (walking,
running, body weight exercise), making it accessible to all. And by understanding the
mechanism by which exercise can exert its effects on attenuating dependence-related
alcohol intake new pharmacological targets and substrates can be discovered and
developed for the treatment of alcohol addiction.
In the previous chapters we tested the hypothesis that limited (2-hr) daily exercise
(wheel running) could attenuate the escalation of alcohol drinking engendered by a model
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of alcohol dependence. Data was provided demonstrating the ability of exercise to
attenuate escalated alcohol intake in a mouse model of alcohol dependence (Chapter 3 &
4). Furthermore, this effect was shown to be mediated through increased BDNF (mRNA
and protein) expression (Chapter 2 & 3) and BDNF-TrkB signaling (Chapter 4).
It was demonstrated (Chapter 2) that limited exercise for 4 or 6 weeks will increase
Bdnf mRNA and protein expression in the mPFC, a region shown to regulate excessive
alcohol intake through increased BDNF signaling (174, 325). Previously published finding
showing a history of exercise caused a “BDNF priming” effect was replicated (137) in our
model using 2-hr daily exercise, demonstrating exercise can rapidly elevate BDNF in the
mPFC of previously exercising mice.
Chapter 3 explored whether limited exercise could attenuate escalated alcohol
intake engendered by a model of alcohol dependence (CIE exposure) (154, 168, 171) and
whether exercise could prevent CIE-induced reductions of Bdnf mRNA in the mPFC (174,
178, 326, 486). Results revealed exercise can prevent the development of alcohol
dependence-related intake and this effect correlated with exercise preventing reductions
of Bdnf mRNA in the mPFC. Suggesting a role of exercise induced BDNF expression in
the mPFC in the attenuation of escalated alcohol intake.
To test the hypothesis that exercise attenuated escalated alcohol intake through
mitigating chronic alcohol related reductions of BDNF in the brain (alcohol dependence
decreases BDNF, exercise increases BDNF), TrkB receptors were antagonized by
systemic administration of ANA-12 (Chapter 4). Blocking TrkB receptors prevented
exercise from attenuating escalated alcohol intake, demonstrating a BDNF-TrkB
mechanism responsible for the preventative effects of exercise.
The evidence presented showed the ability of exercise to prevent dependence
related alcohol intake through a BDNF-TrkB mediated mechanism using systemic,
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pharmacological antagonism of TrkB receptors. Although exercise attenuated escalated
alcohol intake and prevented chronic alcohol exposure from reducing Bdnf mRNA in the
mPFC, this data is highly correlational and does not specifically isolate the role of BDNF
in the mPFC, limiting the interpretation of the results. Additional studies are needed to
determine the specific role of exercise induced BDNF expression in the mPFC in alcohol
dependence related drinking. Specifically blocking BDNF-TrkB signaling in the mPFC of
exercising mice exposed to chronic alcohol. One such study required would use direct
pharmacological antagonism of TrkB receptors or sequestration of BDNF protein using a
scavenger protein (TrkB-Fc) in the mPFC of exercising mice exposed to chronic alcohol
vapor. This would attempt to replicate results from Experiment 4 (Chapter 4) through
specifically targeting the mPFC.
As described in Chapter 1, Bdnf mRNA is trafficked not only throughout the neuron
(276-278, 280), but also to and from the mPFC (267, 268, 492). Therefore, another
limitation in the work presented is that Bdnf mRNA measured in the mPFC may not
correlate to the amount of functional BDNF protein actually found in the mPFC. While
literature shows an inverse relationship between BDNF in the mPFC and alcohol drinking
(174, 178, 325, 326, 486) we did not demonstrate that the Bdnf mRNA measured in the
mPFC was in fact turned into BDNF protein that elicited the attenuation of escalated
alcohol drinking. Studies described in the paragraph above would help to elucidate the
role of exercise induced BDNF in the mPFC in this effect.
In addition to the mPFC, we found BDNF (mRNA and protein) to be upregulated in
the dentate gyrus (DG) after exercise (2-hr/day x 4 weeks) (Chapter 2; Figure 2.4).
Inhibition of the DG has been demonstrated to increase alcohol drinking behavior (496).
Enhancing BDNF in the DG by exercise may suppress escalated alcohol intake by
enhancing DG activity. The work presented in Chapter 3 and 4 focused on BDNF
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expression in the mPFC and not the DG, therefore it can be speculated that the DG may
be involved in the attenuating effects of exercise on alcohol dependence drinking. Studies
replicating work that targeted BDNF in the mPFC (174) should be replicated targeting the
DG to determine the role of BDNF in the DG on alcohol-dependence related drinking.
Studies that pharmacologically target the BDNF-TrkB system (describe above for the
mPFC) should be conducted in the DG to determine how the effects of exercise induced
BDNF expression in the DG affects alcohol dependent drinking. This limitation can be
expanded upon to include other brain regions not investigated that are known to be
involved in addiction related behaviors.
Here the foundation was set, demonstrating a BDNF-TrkB mediated mechanism by
which

exercise

attenuates

dependence-related

alcohol

drinking.

Currently

pharmacological agonism of the TrkB receptors is severely limited, with only a couple of
known molecules (314, 497). Determining a specific mechanism by which exercise
increases BDNF expression will allow for the development of pharmacotherapies and
treatments to target the mechanism to increase BDNF to treat AUD.
One overlapping mechanism is through the ketone body, beta-hydroxybutyrate.
Exercise, fasting, and the high-fat ketogenic diet all result in the metabolism of fat and the
production of beta-hydroxybutyrate (298, 354) which released into the blood stream and
can cross the blood brain barrier (298, 354, 355). Beta-hydroxybutyrate is an HDAC
inhibitor directly linked to increasing the expression of Bdnf mRNA exon I (298). Studies
have administered HDAC inhibitors, e.g. sodium butyrate (beta-hydroxybutyrate analog)
and SAHA, to rodents to reduce escalated alcohol intake (498, 499). This data along with
work showing increasing BDNF in the mPFC can prevent the development of alcohol
dependence and reduce alcohol dependent drinking (174), indicates a potential
mechanism which can be targeted to increase BDNF and reduce drinking. Through the
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high-fat ketogenic diet, beta-hydroxybutyrate levels are elevated in the blood and brain
(298, 354). The ketogenic diet has been demonstrated to reduce alcohol withdrawal
symptoms in rats (500) and the National Institute on Alcohol Abuse and Alcoholism
(NIAAA) is currently funding a clinical trial examining the effects on withdrawal in humans
(NCT03255031). Furthermore, at the recent 2019 Research Society on Alcoholism
conference in Minneapolis, MN unpublished data was presented at Symposia Session
#26 - Alcohol Metabolism and the Role of Ketone Bodies to Alleviate Symptoms of Alcohol
Withdrawal, showing administration of exogenous ketone esters and the ketogenic diet
could reduce craving and withdrawal symptoms. This information provides an additional
natural, noninvasive mechanism by which BDNF levels can be elevated in the brain. Using
fasting or ketogenic diet along with exercise, may work synergistically to reduce and
prevent alcohol dependence drinking. Therefore, future studies could be performed to
investigate the role of beta-hydroxybutyrate in the effects of exercise on BDNF levels and
the attenuation of alcohol-dependence related drinking.
Additionally, exercise induces the browning of fat that produces irisin, a molecule
that has been shown to increase the production of BDNF in the brain (329, 363, 367, 368).
This is another mechanism which was not examined that may explain increases in BDNF
expression detected and therefore makes another interesting mechanism to investigate
for neuropsychiatric and substance use disorders.
Exercise increases the expression and release of multiple neurotransmitters (e.g.
dopamine, norepinephrine, endogenous opioids) (415, 433, 461) in addition to enhancing
BDNF production. It is well established that these other neurotransmitters are involved in
alcohol use and addiction behaviors (Chapter 1, p. 36-45). The current studies only
focused on BDNF-TrkB signaling and so may have overlooked the function of other
exercise induced. Moreover, these signaling molecules have also been shown to positively
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increase BDNF production (Chapter 1, p. 36-45). Future studies could be performed to
examine how manipulation of these alternative signaling molecules, induced by exercise,
could regulate alcohol intake. These studies could go further to determine if there is a
relationship between neurotransmitter production and BDNF expression. Additionally,
these other signaling molecules and pathways may provide better pharmacological targets
which can still result in the enhancement of BDNF in the brain.
Another limitation to the studies presented is they only examined the effect of
exercise as a treatment for alcohol dependence in mice that had a prior history of exercise.
This limits the interpretation of the data for two reasons: 1) A history of exercise primes
the BDNF system so that even after a period of inactivity, a single bout of exercise will
rapidly elevate BDNF in rodents with a history of exercise (137) (Figure 4 A & B); 2) Human
alcoholics have reduced BDNF in their blood (315, 316) and may require more bouts of
exercise to sufficiently raise BDNF levels high enough, for a long enough duration to elicit
a reduction in drinking.
However, exercise can still play an important, beneficial role in the maintenance of
abstinence and in preventing the development of alcohol abuse and addiction. Future
experiments should be pursued to evaluate the ability of exercise to reduce alcoholdependence related drinking performed by alcohol dependent mice without prior exercise
experience. This may prove to be more difficult to determine in mice using the
methodology in the previous chapters, because as seen in Figure 13, as mice are exposed
to repeated cycles of CIE, wheel running activity begins to decline. If mice are uncapable
or unwilling to perform exercise, the benefits of exercise cannot be realized. To overcome
this possible scenario, an alternative strategy of using forced treadmill exercise could be
implemented.
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Daily voluntary exercise increases BDNF expression in the brain of mice and can
attenuate the escalation of alcohol intake caused by alcohol dependence (CIE vapor
exposure). Data was provided demonstrating escalated alcohol-dependent intake is
mediated through a BDNF-TrkB mediated signaling mechanism. Furthermore, we
provided data to implicate the mPFC as a potential brain region through which exercised
induced BDNF expression may exert its protective effects against the development of
alcohol dependence. These data add to the growing body of literature revealing a
therapeutic role of exercise in the treatment of alcohol dependence and provides data
which indicates a role of BDNF in the mPFC in this effect.
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